

Curriculum Vitae**Peter W. F. Wilson, M.D.****Work VA Office**

Dir. Epidemiology & Genomic Medicine
 Atlanta VAMC
 Room 5A140
 1670 Clairmont Rd
 Decatur, GA 30022

Work Emory Office

Emory Clinical Cardiovascular
 Research Institute
 1462 Clifton Rd
 Room 505
 Atlanta, GA 30322

Education and Certification

- a) B.S. Yale College, 1970
- b) M.D. Univ. of Texas Medical School at San Antonio, 1974
- c) Diplomate of American Board of Internal Medicine 1977, Advanced Achievement in Internal Medicine 1987
- d) Certified in Endocrinology and Metabolism, American Board of Internal Medicine 1981
- e) Licensed to practice medicine in Maryland 1978, Massachusetts 1983, South Carolina 2003, Connecticut 2008, Georgia 2008
- f) Special Purpose Examination (SPEX) certified 2004.

Postgraduate Medical Training

- a) Medical Internship, Duke Medical Center, 1974-5
- b) Medical Jr. Assistant Residency, Duke Medical Center, 1975-6
- c) Clinical Endocrinology Fellowship, Duke Medical Center, 1976-7
- d) Medical Sr. Assistant Residency, Duke Medical Center, 1977-8
- e) Staff Associate in Epidemiology, National Heart, Lung, and Blood Institute, Bethesda, MD 1978-80

Postgraduate Medical Employment

- a) Medical Officer in Clinical and Genetic Epidemiology Section, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD 1980-1983 and Framingham, MA 1983-1999
- b) Assistant Professor of Medicine, Uniformed Services University of the Health Sciences, 1982-1983
- c) Temporary Adviser to the World Health Organization for Multinational Study of Vascular Disease in Diabetes, 1981
- d) Director of Laboratories, Framingham Heart Study, Framingham, MA 1983-
- e) Lecturer in Preventive Medicine and Epidemiology, Harvard Medical School, 1984-1995
- f) Clinical Associate Professor of Medicine, Tufts University School of Medicine 1987-1999
- g) Adjunct Assistant Professor of Medicine, Baylor College of Medicine, 1991-1992
- h) Associate Professor of Medicine, Boston University School of Medicine 1994-1999
- i) Professor of Medicine, Boston University School of Medicine 2000-2003
- j) Program Director, General Clinical Research Center, Medical University of South Carolina 2003-2005
- l) Professor of Medicine, Medical University of South Carolina 2003-2006
- m) Vice Chair of Medicine (Research), Medical University of South Carolina 2005-2006
- n) Professor of Medicine (Cardiology Section), Professor of Public Health (Global Health, Epidemiology), Emory University, Atlanta, GA 2006-
- o) Director of Epidemiology and Genomic Medicine, Atlanta VAMC, Atlanta, GA 2006-

Postgraduate Medical Education

- a) Epidemiology 1, Johns Hopkins School of Public Health, 1978
- b) Epidemiology Summer session, Univ. of Minnesota, 1979 taking courses in cardiovascular epidemiology, genetics and epidemiology, and advanced statistical techniques
- c) Epidemiology 2, Johns Hopkins School of Public Health, 1980
- d) Short Course in Mammalian and Human Genetics, Bar Harbor, ME, 1980
- e) Fellow at 14th International Ten Day Course-Cardiovascular Epidemiology, Heidelberg, W. Germany, 1981

Honors and Awards

- a) Pauerstein Merit Scholarship Award by Medical School faculty for performance during third year of medical school (1973)
- b) Mosby Scholarship Book Award for top five ranking students during fourth year of medical school (1974)
- c) Alpha Omega Alpha honor medical society (1974)
- d) U.S. Public Health Service-- Citation Award (1989), Commendation Medal (1994)
- e) Who's Who in America (2000)
- f) ISI Highly Cited author [Clinical Medicine] for 1983-2003 and Thomson Reuters 2003-2013
- g) Elected to the Association of American Physicians (2005)
- h) Agatston Award (2017)—Society of Cardiovascular Computerized Tomography

Professional Societies and Committees

Organizations: American Diabetes Association (Professional member 1986-), American College of Physicians (Member 1977-), American Heart Association--Prevention Conference (1988), Cholesterol Facts (1989), Special Study Section (1989), Massachusetts Cholesterol Task Force (1993-1999), Epidemiology and Prevention Council: Fellow (1985), AHA Spring Epidemiology Conference Program (Vice-Chair 2005-2006, Chair 2007-2008), AHA Nutrition and Physical Activity Council: Fellow (2007), Fall Sessions Program (Vice-Chair 2005-2006, Chair 2007-2008), AHA Expert Committee on Risk Factors and Subclinical Vascular Disease (Vice-chair 2006-2007, Chair 2008-2009), AHA Council of Committees (2007-2009), North American Association for the Study of Obesity (Fellow 2003), American Society Preventive Cardiology (Secretary 2006-2008, President 2008-2010)

Editorial Boards: Atherosclerosis, Thrombosis, and Vascular Biology(1999–2002), American Journal of Cardiology(2000-2002), Current Opinion in Cardiology(2001-2002), Journal of Clinical Endocrinology and Metabolism (2006-), Journal of Clinical Lipidology (2007-), Endocrine Today (2007-)

Licensure

Massachusetts (#56404), South Carolina (#26554), Connecticut (#047076), Georgia (#61875)

References

Author or co-author of more than 600 scientific articles

Bibliography

- 1 Eisenbarth G, **Wilson P**, Ward F, Lebovitz HE: HLA type and occurrence of disease in familial polyglandular failure. *N Engl J Med* 1978; 298: 92-94
- 2 **Wilson PW**, Easley RS, Bolander FF, Hammond C: Evidence for a hypothalamic defect in Septo-Optic Dysplasia. *Arch Intern Med* 1978; 138: 1276-1277
- 3 **Wilson PW**, Berry WR, Rosse WF: Splenectomy in sickle-cell disease (letter) *Ann Intern Med* 1979; 91: 320
- 4 Eisenbarth GS, **Wilson PW**, Ward F, Buckley C, Lebovitz HE: The Polyglandular Failure Syndrome: Disease inheritance, HLA type and immune function. Studies in patients and families. *Ann Intern Med* 1979; 91: 528-533
- 5 **Wilson PW**: Factors associated with the prevalence of CHD in young men. The Framingham Offspring Study. *ACCEL Tapes* 1980; 12:1
- 6 **Wilson PW**, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB: Prevalence of coronary heart disease in the Framingham Offspring Study. The role of lipoprotein cholesterol. *Am J Cardiol* 1980; 46: 649-654
- 7 Garrison RJ, **Wilson PW**, Castelli WP, Feinleib M, Kannel WB, McNamara PM: Obesity and lipoprotein cholesterol in the Framingham Offspring Study. *Metabolism* 1980; 29: 1053-1060
- 8 **Wilson PW**, Buckley CE, Eisenbarth GS: Disordered immunoregulation in patients with Polyglandular Failure. *J Clin Endo and Metab* 1981; 52: 284-288
- 9 **Wilson PW**, McGee DL, Kannel WB: Obesity, very low density lipoproteins, and glucose intolerance: The Framingham Study. *Am J Epidemiol* 1981; 114: 697-704
- 10 **Wilson PW**, Abbott RD, Garrison RJ, Castelli WP: Estimation of very low density lipoprotein cholesterol from data on triglyceride concentration in plasma. *Clin Chem* 1981; 27: 2008-2010
- 11 Havlik RJ, **Wilson PW**, Garrison RJ, Feinleib M: Epidemiology of lipoproteins and the decline in coronary heart disease mortality. in Lipoproteins and Coronary Atherosclerosis eds. G. Nosedá, C. Fragiácomó, R. Fumagalli, and R. Paoletti (1982) Elsevier Biomedical Press B.V. pp 61-68
- 12 Abbott RD, Garrison RJ, **Wilson PW**, Castelli WP: Coronary heart disease risk. The importance of joint relationships among cholesterol levels in individual lipoprotein classes. *Prev Med* 1982; 11: 131-141
- 13 **Wilson PWF**, Savage DD, Castelli WP, Garrison RJ, Donahue RP, Feinleib M: HDL-Cholesterol in a sample of black adults: The Framingham Minority Study. *Metabolism* 1983; 32: 328-332
- 14 Abbott RD, Garrison RJ, **Wilson PWF**, Epstein FH, Castelli WP, Feinleib M, LaRue CL: The joint distribution of lipoprotein cholesterol classes: The Framingham Study. *Arteriosclerosis* 1983; 3: 261-272
- 15 **Wilson PWF**, Garrison RJ, Abbott RD, Castelli WP: Factors associated with lipoprotein cholesterol levels: The Framingham Study. *Arteriosclerosis* 1983; 3: 273-281
- 16 Savage DD, Devereux RB, Donahue R, Joiner G, Anderson SJ, Rosen RA, **Wilson P**, Kramer R, Brown T, Garrison R, Castelli WP, Feinleib M: Mitral valve prolapse in blacks. *J Natl Med Assoc* 1982; 74: 895-900
- 17 Hoeg JM, Schaefer EJ, Romano CA, Bou E, Píkus AM, Zech LA, Bailey KR, Gregg RE, **Wilson PWF**, Sprecher DL, Grimes AM, Sebring NG, Ayres EJ, Jahn CE, Brewer Jr HB: Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. *Clin Pharm and Ther* 1984; 36: 555-565
- 18 Kannel WB, **Wilson P**, Blair SN: Epidemiological needs in assessment of the role of physical activity and fitness in development of cardiovascular disease *Amer Heart J.* 1985; 109: 875-885
- 19 **Wilson PWF**, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Brewer Jr HB: Estimation of VLDL-Cholesterol in Hyperlipidemia. *Clin Chim Acta* 1985; 151: 285-291
- 20 **Wilson PWF**, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity: The Framingham Study. *N Engl J Med* 1985; 313: 1038-1043

- 21 **Wilson PWF**, Kannel WB, Anderson KM: Lipids, glucose intolerance and vascular disease: The Framingham Study Karger monographs on Atherosclerosis, Vol 13. Dyslipoproteinemias and diabetes. pp 1-11, (Karger, Basel 1985)
- 22 Grab B, Grabauskas V, Jarrett RJ, Keen H, Teuscher A, **Wilson PWF**: Prevalence of small vessel and large vessel disease in diabetic patients from fourteen centres: The World Health Organization Multinational Study of Vascular Disease in Diabetes. *Diabetologia* 1985; 28: 615-640
- 23 Ordovas JM, Schaefer EJ, Salem D, Ward R, Glueck CJ, Vergani C, **Wilson PWF**, Karathanasis SK: Apolipoprotein A-I gene polymorphism in the 3' flanking region associated with familial hypoalphalipoproteinemia and premature coronary artery disease. *N Engl J Med* 1986; 314: 671-677
- 24 **Wilson PWF**, Anderson KM, Kannel WB: The epidemiology of diabetes mellitus in the elderly: The Framingham Study. *Amer J Med* 1986; 80 (5A): 3-9
- 25 Kannel WB, Garrison RJ, **Wilson PWF**: Obesity and nutrition in the diabetic elderly. *Amer J Med* 1986; 80 (5A): 22-30
- 26 **Wilson PWF**, Paffenbarger Jr RS, Morris JN, Havlik RJ: Assessment methods for physical activity and physical fitness in population studies: Report of a NHLBI workshop. *Amer Heart J* 1986; 111: 1177-1192
- 27 **Wilson PWF**: The cholesterol-to-coronary-risk connection. *Masters in Cardiology* 1986; 3: 10-13
- 28 **Wilson PWF**, Garrison RJ, Castelli WP: Postmenopausal estrogen use and heart disease (letter) *N Engl J Med* 1986; 315; 135 and 1987; 316: 343
- 29 Castelli WP, Garrison RJ, **Wilson PWF**, Abbott RD, Kalousdian S, Kannel WB: Coronary heart disease incidence and lipoprotein cholesterol levels: The Framingham Study *JAMA* 1986; 256: 2835-2838
- 30 Ordovas JM, Litwack-Klein L, **Wilson PWF**, Schaefer EJ: Apolipoprotein E isoform phenotyping methodology and population frequency with identification of ApoE1 and ApoE5 Isoforms in the Framingham Offspring Study. *J Lipid Res* 1987; 28: 371-380
- 31 **Wilson PWF**, Castelli WP, Kannel WB: Cardiovascular risk prediction in adults: The Framingham Heart Study. *Am J Cardiol* 1987; 59: 91G-94G
- 32 Kiel DP, Felson D, Anderson JJ, **Wilson PWF**, Moskowitz MA: Postmenopausal estrogen use and hip fracture: The Framingham Study. *N Engl J Med* 1987; 317: 1169-1174
- 33 Anderson KM, **Wilson PWF**, Garrison RJ, Castelli WP: Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample: The Framingham Offspring Study. *Atherosclerosis* 1987; 68: 59-66
- 34 McNamara JR, Campos H, Ordovas JM, Peterson J, **Wilson PWF**, Schaefer EJ: Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. *Arteriosclerosis* 1987; 7: 483-490
- 35 Ordovas JM, Peterson JP, Santaniello P, Cohn JS, **Wilson PWF**, Schaefer EJ: Enzyme-linked immunosorbent assay for human plasma apolipoprotein B. *J Lipid Res* 1987; 28: 1216-1224
- 36 Teuscher A, Schnell H, **Wilson PWF**: Eight year incidence of diabetic retinopathy in 358 Swiss Diabetics. *Diabetes Care* 1988; 11: 246-251
- 37 Abbott RD, **Wilson PWF**, Kannel WB, Castelli WP: High density lipoprotein cholesterol, total cholesterol, and myocardial infarction: The Framingham Study. *Arteriosclerosis* 1988; 8: 207-211
- 38 Hiller R, Sperduto RD, Podgor MJ, Ferris FL III, **Wilson PWF**: Diabetic retinopathy and cardiovascular disease in Type II diabetics. The Framingham Heart Study and the Framingham Eye Study. *Amer J Epidemiol* 1988; 128: 402-409
- 39 Campos H, McNamara JR, **Wilson PWF**, Ordovas JM, Schaefer EJ: Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. *J Clin Endo Metab* 1988; 67: 30-35
- 40 **Wilson PWF**, Abbott RD, Kannel WB, Castelli WP: High density lipoprotein cholesterol and mortality: The Framingham Study. *Arteriosclerosis* 1988; 8: 737-741

- 41 Abbott RD, Donahue RP, Kannel WB, **Wilson PWF**: The impact of diabetes on survival following myocardial infarction in men versus women: The Framingham Study. *JAMA* 1988; 260: 3456-3460
- 42 Dannenberg AL, Keller JB, **Wilson PWF**, Castelli WP: Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates. *Amer J Epid* 1989; 129: 76-87
- 43 Abbott RD, Levy D, Kannel WB, Castelli WP, **Wilson PWF**, Garrison RJ, Stokes III J: Cardiovascular risk factors and graded treadmill exercise endurance in healthy adults: The Framingham Offspring Study. *Am J Cardiol* 1989; 63: 342-346
- 44 **Wilson PWF**, Garrison RJ, Kannel WB, McGee DL, Castelli WP: Is coffee consumption a contributor to cardiovascular disease: insights from the Framingham Study. *Arch Intern Med* 1989; 149: 1169-1172
- 45 Castelli WP, **Wilson PWF**, Levy D, Anderson K: Cardiovascular risk factors in the elderly. *Am J Cardiol* 1989; 63: 12H-19H
- 46 Felson DT, Anderson JJ, Hannan MT, Milton RC, **Wilson PWF**, Kiel DP: Impaired vision and hip fracture: The Framingham Study. *J Amer Geriatric Soc* 1989; 37: 495-500
- 47 **Wilson PWF**, Christiansen JC, Anderson KM, Kannel WB: Impact of national guidelines for cholesterol risk factor screening: The Framingham Offspring *JAMA* 1989; 262: 41-44 (letter *JAMA* 1989; 262: 2998)
- 48 Blair SN, Kannel WB, Kohn HW, Goodyear N, **Wilson PWF**: Surrogate measures of physical activity and physical fitness: Evidence for sedentary traits of resting tachycardia, obesity, and low vital capacity. *Am J Epidemiol* 1989; 129: 1145-56
- 49 Schaefer EJ, Moussa PB, **Wilson PWF**, McGee D, Dallal G, Castelli WP: Plasma lipoproteins in health octogenarians: Lack of reduced high density lipoprotein cholesterol levels. Results from the Framingham Heart Study. *Metabolism* 1989; 38: 293-296
- 50 **Wilson PWF**: Mild hypertension accompanied by other risk factors for coronary disease. *Management Options in Cardiology*. 1989; 1: 1-4
- 51 Breslow JL, Deeb S, Lalouel JM, LeBoeuf R, Schaefer EJ, Tyroler HA, **Wilson P**, Young S: AHA Conference Report on Cholesterol: Workshop II: Genetic susceptibility to atherosclerosis. *Circulation* 1989; 80: 724-728
- 52 Fabsitz RR, Nam J-M, Gart J, Stunkard A, Price RA, **Wilson PWF**: HLA Associations with obesity. *Human Heredity* 1989; 39: 156-164
- 53 **Wilson PWF**: The epidemiology of hypercholesterolemia: a global perspective. *Amer J Med* 1989; 87 (suppl 4A): 5S-13S
- 54 Kaufman HW, McNamara JR, Anderson KM, **Wilson PWF**, Schaefer EJ: How reliably can compact chemistry analyzers measure lipids? *JAMA* 1990; 263: 1245-1249 (letters *JAMA* 1990; 264: 1101-1103)
- 55 McNamara JR, Cohn JS, **Wilson PWF**, Schaefer EJ: Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. *Clin Chem* 1990; 36: 36-42
- 56 Levy D, **Wilson PWF**, Anderson KM, Castelli WP: Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. *Amer Heart J* 1990; 119: 712-717
- 57 Gotto AM, LaRosa JC, Hunnigake D, Grundy SM, **Wilson PW**, Clarkson TB, Hay JW. The Cholesterol Facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National, Heart, Lung, and Blood Institute. *Circulation* 1990; 81: 1721-1733
- 58 **Wilson PWF**: Importance of lipid fractions for coronary morbidity and mortality. in Cholesterol and Prevention Primaire: A qui s'adressent les régimes de prévention cardiovasculaire? Colloque International-Département Santé du CIDIL. Paris, France 1990, pp 73-80
- 59 Genest JJ, Ordovas JM, McNamara JR, Robbins AM, Meade T, Cohn SD, Salem DN, **Wilson PWF**, Masharani U, Frossard PM, Schaefer EJ: DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease. *Atherosclerosis* 1990; 82: 7-17

- 60 Donahue RP, Abbott RD, **Wilson PWF**: Effect of diuretic use on the development of diabetes mellitus. The Framingham Study. in Effects of Antihypertensive treatment on glucose metabolism. Thieme Medical Publishers 1990 (New York) pp 46-48
- 61 Jones MG, Anderson KM, **Wilson PW**, Kannel WB, Hindman NB, Wagner GS: Mortality after recognized myocardial infarction . The prognostic use of a QRS scoring system in the Framingham Study. *Am J Cardiol* 1990; 66: 546-550
- 62 **Wilson PWF**: High-density lipoprotein, low density lipoprotein and coronary artery disease. *Am J Med* 1990; 66: 7A-10A
- 63 Kiel DP, Felson DT, Hannan MT, Anderson JJ, **Wilson PWF**: Caffeine intake and the risk of hip fracture: The Framingham Study. *Amer J Epidemiol* 1990; 132: 675-684
- 64 Kannel WB, D'Agostino RB, **Wilson PWF**, Belanger AJ: Diabetes, fibrinogen and risk of cardiovascular disease. The Framingham experience. *Amer Heart J* 1990; 120: 672-676
- 65 **Wilson PWF**, Castelli WP: Coronary heart disease--The view from Framingham, in Coronary Risk Factors Revisited eds. Shepherd J, Packard CJ, McEwan SR, and Brownlie SM, Excerpta Medica (Amsterdam), 1989, pp 3-14
- 66 Anderson KM, Dumphy DC, **Wilson PWF**: Management of data quality in a long-term epidemiologic study: The Framingham Heart Study. in Data Quality Control: Theory and Pragmatics. eds Liepins GE and Uppuluri V.R.R., Marcel Dekker, New York, NY, 1990, pp 57-68
- 67 Anderson KM, **Wilson PWF**, Odell PM, Kannel WB: An updated coronary risk profile. a statement for health professionals. *Circulation* 1991; 83: 356-362
- 68 Anderson KM, Odell PM, **Wilson PWF**, Kannel WB: Cardiovascular disease risk profiles. *Am Heart J* 1991; 121: 293-298
- 69 **Wilson PWF**, Anderson KM, Castelli WP, Kannel WB: Twelve year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: The Framingham Offspring Study. *Amer J Med* 1991; 90: 11-16
- 70 **Wilson PWF**, Cupples LA, Kannel WB: Is hyperglycemia associated with cardiovascular disease? The Framingham Heart Study *Amer Heart J* 1991; 121: 586-590
- 71 **Wilson PWF**, Anderson KM: HDL cholesterol and triglycerides as risk factors for CHD, in Atherosclerosis and Cardiovascular Disease, 7th International Meeting eds Descovich GC, Gaddi A, Magri GL, Lenzi S. Kluwer Academic Publishers, Dordrecht, 1990, pp 609-615
- 72 Sawin CT, Geller A, Kaplan MM, Bacharach P, **Wilson PWF**, Hershman JM: Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism *Arch Intern Med* 1991; 151: 165-168
- 73 **Wilson PWF**, Anderson KM, Castelli WP: The impact of triglycerides on coronary heart disease. The Framingham Study. *Atherosclerosis Reviews* 1991; 22: 59-63
- 74 Kannel WB, **Wilson PWF**, Zhang T-J: The epidemiology of impaired glucose tolerance. *Am Heart J* 1991; 121: 1268-1273
- 75 Genest JJ Jr, Jenner JL, McNamara JR, Ordovas JM, Silberman SR, **Wilson PWF**, Schaefer EJ: Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease *Am. J. Cardiol* 1991; 67: 1039-1045
- 76 Campos H, **Wilson PWF**, Jimenez D, McNamara JR, Ordovas JM, Schaefer EJ: Differences in apolipoproteins and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: results from the Framingham Offspring Study. *Metabolism* 1990; 39: 1033-1038
- 77 Genest JJ, McNamara JR, Salem DN, **Wilson PWF**, Schaefer EJ, Malinow MR: Plasma homocyst(e)ine levels in men with premature coronary artery disease, *JACC* 1990; 16: 1114-1119
- 78 Galderisi M, Anderson KM, **Wilson PWF**, Levy D: Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study) *Am. J. Cardiol* 1991; 68: 85-89
- 79 Wong ND, **Wilson PWF**, Kannel WB: Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study *Ann. Intern. Med.* 1991; 115: 687-693

- 80 Genest JJ Jr, Bard JM, Fruchart J-C, Ordovas JM, **Wilson PWF**, Schaefer EJ: Plasma apolipoprotein A-I, A-II, B, E and CIII containing particles in men with premature coronary artery disease. *Atherosclerosis* 1991; 90: 149-157
- 81 Felson DT, Hannan MT, Naimark A, Berkeley J, Gordon G, **Wilson PWF**, Anderson J: Occupational physical demands, knee bending, and knee osteoarthritis: results from the Framingham Study. *J. Rheumatol.* 1991; 18: 1587-1592
- 82 Campos H, Willett WC, Peterson RM, Siles X, Bailey SM, **Wilson PWF**, Posner BM, Ordovas JM, Schaefer EJ. Nutrient intake comparisons between Framingham and rural and urban Puriscal, Costa Rica: associations with lipoproteins, apolipoproteins, and low density lipoprotein particle size. *Arteriosclerosis and Thrombosis* 1991; 11: 1089-1099
- 83 Castelli WP, Anderson K, **Wilson PWF**, Levy D: Lipids and risk of coronary heart disease: The Framingham Study. *Ann. Epidemiol* 1992; 2: 24-28
- 84 D'Agostino RB, Cobb JL, Wolf PA, **Wilson PWF**: Aspirin use and cardiovascular disease in women. *JAMA (letter)* 1992; 267: 364
- 85 Singer DE, Nathan DM, Anderson KM, **Wilson PWF**, Evans JC: Association of hemoglobin A1C with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. *Diabetes* 1992; 41: 202-208
- 86 Kannel WB, Anderson K, **Wilson PWF**: White blood cell count and cardiovascular disease: insights from the Framingham Study *JAMA* 1992; 267: 1253-1256
- 87 Lamou-Fava S, Jimenez D, Christian JC, Fabsitz RR, Reed T, Carmelli D, Castelli WP, Ordovas JM, **Wilson PWF**, Schaefer EJ: The NHLBI Twin Study: Heritability of apolipoprotein A-I, B, and low density lipoprotein subclasses and concordance for lipoprotein (a). *Atherosclerosis* 1991; 91: 97-106
- 88 Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM **Wilson PWF**, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. *Arteriosclerosis* 1992; 12: 187-195
- 89 **Wilson PWF**, Kannel WB: Heterogeneity of so-called essential hypertension. *Hypertension Index and Reviews* 1992; 2: (No.5); 1-2
- 90 Haskell WL, Leon AS, Caspersen CJ, Froehlicher VF, Hagberg MJ, Harlan W, Holloszy JO, Regensteiner JG, Thompson PD, Washburn RA, **Wilson PWF**: Cardiovascular benefits and assessment of physical activity and physical fitness in adults. *Medicine and Science in Sports and Exercise* 1992; 24: S201-S220
- 91 **Wilson PWF**, Kannel WB: Epidemiology of hyperglycemia and atherosclerosis. in Hyperglycemia, Diabetes, and Vascular Disease, eds Ruderman, Williamson and Brownlee, Oxford Univ. Press (1992) pp 31-38
- 92 Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, **Wilson PWF**, Salem DN, Schaefer EJ: Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease *JACC* 1992; 19: 792-802
- 93 Civeira F, Genest J, Pocovi M, Salem DN, Herbert PN, **Wilson PWF**, Schaefer EJ, Ordovas JM: The MspI restriction fragment length polymorphism 3' to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease. *Atherosclerosis* 1992; 92: 165-176
- 94 Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, Pocovi M, Frossard PM, Masharani U, **Wilson PWF**, Salem DN, Ward RH, Schaefer EJ: Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. relationships with lipids, apolipoproteins, and premature coronary artery disease *Atherosclerosis* 1991; 87: 75-86
- 95 Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, **Wilson PWF**, Salem DN, Schaefer EJ: Familial lipoprotein disorders in patients with premature coronary artery disease. *Circulation* 1992; 85: 2025-2033
- 96 Kannel WB, **Wilson PWF**: Efficacy of lipid profiles in predicting coronary disease. *Am. Heart J* 1992; 124: 768-774
- 97 Thompson GR, **Wilson PWF**: Coronary Risk Factors and Their Assessment. Science Press, London, 1992

- 98 Garrison RJ, Gold RS, **Wilson PWF**, Kannel WB: Educational attainment and coronary heart disease risk: The Framingham Offspring Study. *Prev. Med.* 1993; 22: 54-64
- 99 **Wilson PWF**, Kannel WB: Is baldness bad for the heart? (editorial) *JAMA* 1993; 269: 1035-1036
- 100 Roubenoff R, **Wilson PWF**: Advantage of knee height over height as an index of stature in expression of body composition in adults. *Am J Clin Nutr* 1993; 57: 609-613
- 101 **Wilson PWF**, Kannel WB: Hypercholesterolemia and coronary risk in the elderly: the Framingham Study. *Am. J. Geriatr. Cardiol.* 1993; 2: 52-56
- 102 Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, **Wilson PWF**, Castelli WP, Schaefer EJ: Effects of age, gender, and menopausal status on plasma lipoprotein (a) levels: The Framingham Offspring Study *Circulation* 1993; 87: 1135-1141
- 103 Schaefer EJ, Genest JJ Jr, Ordovas JM, Salem DN, **Wilson PWF**: Familial lipoprotein disorders and premature coronary artery disease. *Current Opinion in Lipidology* 1993; 4: 288-298
- 104 Shively CA, Knox SE, Sherwin BB, Walsh BW, **Wilson PWF**: Sex steroids, psychosocial factors, and lipid metabolism. *Metabolism* 1993; 42 (supp 1): 16-24
- 105 Felson DT, Zhang Y, Hannan MT, Kiel DP, **Wilson PWF**, Anderson JJ: The effect of postmenopausal estrogen therapy on bone density in elderly women. *N Engl J Med* 1993; 329: 1141-1146
- 106 Campos H, McNamara JR, Ordovas JM, Posner BM, **Wilson PWF**, Castelli WP, Schaefer EJ: LDL particle size distribution. Results from the Framingham Offspring Study. *Arterioscler. Thromb.* 1992; 12: 1410-1419
- 107 Posner BM, Cupples LA, Gagnon D, **Wilson PWF**, Chetwynd K, Felix D: Healthy People 2000. The rationale and potential efficacy of preventive nutrition in heart disease: the Framingham Study *Arch. Intern. Med* 1993; 153: 1549-1556
- 108 Vaziri SM, Evans JC, Larson MG, **Wilson PWF**: The impact of female hormone usage on the lipid profile: the Framingham Offspring Study *Arch. Intern. Med* 1993; 153: 2200-2206
- 109 Selhub J, Jacques PF, **Wilson PWF**, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in the elderly *JAMA* 1993; 270: 2693-2698
- 110 Lyu L-C, Shieh M-J, Ordovas JM, Lichtenstein AH, **Wilson PWF**, Schaefer EJ: Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham. *Arterioscler. Thromb.* 1993; 13: 1429-1440
- 111 **Wilson PWF**, Evans JC: Coronary artery prediction. *Amer J Hypertension* 1993; 6: 309S-311S
- 112 **Wilson PWF**: Total Cardiovascular Risk in Hypertension Primer: The Essentials of High Blood Pressure. eds Izzo JL and Black HR. American Heart Association 1993 Chapter C17, pp 190-191
- 113 McNamara JR, Jenner JL, Li Z, **Wilson PWF**, Schaefer EJ: Change in LDL particle size is associated with change in plasma triglyceride concentration *Arterioscler. Thromb.* 1992; 12: 1284-1290
- 114 Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, **Wilson PWF**, Kelly-Hayes M, Wolf PA, Kreger BE, Milton RC, Kannel WB: Comorbidity and physical disability in the elderly: a disease- and task-specific comparison. *Amer J Publ Hlth* 1994; 84: 351-358
- 115 Kreger BE, D'Agostino RB, Odell P, **Wilson PWF**: Long-term intraindividual cholesterol variability: Natural course and adverse impact on morbidity and mortality-- The Framingham Study. *Am Heart J.* 1994; 127:1607-1614
- 116 **Wilson PWF**, Larson MG, Castelli WP: Triglycerides, HDL-C and coronary heart disease: a Framingham update on their interrelationships. *Canadian J. Cardiology* 1994; 10: 5B-9B
- 117 Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, **Wilson PWF**: Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. *J Lipid Res* 1994; 35: 779-792
- 118 Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, **Wilson PWF**: Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: Results from the Framingham Offspring Study *Arterioscler. Thromb.* 1994; 14: 1105-1113

- 119 **Wilson PWF**: Established risk factors and coronary heart disease: the Framingham Study *Amer J Hypertension* 1994; 7: 7S-12S
- 120 The Framingham Offspring Eye Study Group. Familial aggregation of lens opacities: The Framingham Eye Study and the Framingham Offspring Eye Study *Am J Epidemiol* 1994; 140: 555-564
- 121 Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, **Wilson PWF**, Benjamin EJ, D'Agostino RB: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* 1994; 331: 1249-1252
- 122 Lindenbaum J, Rosenberg IH, **Wilson PW**, Saha JR, Stabler SP, Allen RH: Prevalence of cobalamin deficiency in the Framingham elderly population. *Am J Clin Nutr* 1994; 60: 2-11
- 123 Bostom AG, Gagnon DR, Cupples LA, **Wilson PWF**, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP: A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study *Circulation* 1994; 90: 1688-1695
- 124 **Wilson PWF**, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ: Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart Disease: The Framingham Offspring Study. *JAMA* 1994; 272: 1666-1671
- 125 Kannam JP, Levy D, Larson M, **Wilson PWF**: Short stature and risk for mortality and cardiovascular disease events: the Framingham Heart Study. *Circulation* 1994; 90: 2241-2247
- 126 **Wilson PWF**, Anderson KM, Harris T, Kannel WB, Castelli WP: Determinants of change in total cholesterol and HDL-C with age: The Framingham Study. *Journal of Gerontology: Medical Sciences* 1994; 49: 252-257
- 127 **Wilson PWF**: Relation of high-density lipoprotein subfractions and apolipoprotein E isoforms to coronary disease. *Clin Chem* 1995; 41: 165-169
- 128 Garrison RJ, Sawin CT, **Wilson PWF**, Kannel WB: Plasma estradiol in premenopausal women: The Framingham Offspring Study. *Journal of Women's Health* 1995; 3: 435-443
- 129 Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, **Wilson PWF**: Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. *J Lipid Res* 1994; 35: 871-882
- 130 Lyu L-C, Shieh M-J, Posner BM, Ordovas JM, Dwyer JT, Lichtenstein AH, Cupples LA, Dallal GE, **Wilson PWF**, Schaefer EJ: Relationship between dietary intake, lipoproteins, and apolipoproteins in Taipei and Framingham. *Am J Clin Nutr* 1994; 60: 765-774
- 131 Rodriguez CR, Seman LJ, Ordovas JM, Jenner J, Genest JJ Jr, **Wilson PWF**, Schaefer EJ: Lipoprotein(a) and coronary heart disease. *Chem Phys Lipids* 1994; 67: 389-398
- 132 Selhub J, Jacques PF, Bostom AG, D'Agostino RB, **Wilson PWF**, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH: Association between plasma homocysteine and extracranial carotid stenosis. *N Engl J Med* 1995; 332: 286-291
- 133 Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, **Wilson PWF**, Levy D, Muller JE, Tofler GH: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study *Circulation* 1995; 91:1952-1958
- 134 Kannel WB, **Wilson PWF**: Risk factors that attenuate the female coronary disease advantage *Arch Intern Med* 1995; 155: 57-61
- 135 **Wilson PWF**, Kannel WB: Hypertension, other risk factors, and the risk of cardiovascular disease. Chapter 7 in Hypertension: Physiology, Diagnosis, and Management. Second Edition, eds Laragh JH and Brenner BM. Raven Press, New York 1995, pp 99-114
- 136 Roubenoff R, Dallal GE, **Wilson PWF**: Predicting body fatness: the body mass index vs estimation by bioelectrical impedance. *Am J Publ Hlth* 1995; 85: 726-728

- 137 Li-Ching L, Posner BM, Shieh M-J, Lichtenstein AH, Cupples LA, Dwyer JT, **Wilson PWF**, Schaefer EJ: Cross-cultural comparisons between Taipei Chinese and Framingham Americans: dietary intakes, blood lipids and apolipoproteins. *Asia Pacific J Clin Nutr* 1994; 3: 119-125
- 138 Myers RH, Schaefer EJ, **Wilson PWF**, D'Agostino R, Bachman DL, Ordovas JM, Au R, Cobb JL, Wolf PA: Apolipoprotein E allele 4 is associated with dementia in the Framingham Study in Research Advances in Alzheimer's disease and Related Disorders eds Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, Wiley & Sons 1995, pp 63-70
- 139 Kannel WB, **Wilson PWF**: An update on coronary risk factors. *Med Clin N America* 1995; 79: 951-971
- 140 **Wilson PWF**: Cholesterol screening: Once is not enough. (editorial) *Archives of Internal Medicine Arch Intern Med* 1995; 155: 2146-2147
- 141 Podgor MJ, Hiller R, Framingham Eye Studies Group: Associations of types of lens opacities between and within eyes of individuals: an application of second-order generalized estimating equations. *Statistics in Medicine* 1996; 15: 145-156
- 142 Welty FK, Ordovas J, Schaefer EJ, **Wilson PWF**, Young SG: Identification and molecular analysis of two ApoB gene mutations causing low plasma cholesterol levels. *Circulation* 1995; 92: 2036-2040
- 143 Myers RH, Schaefer EJ, **Wilson PWF**, D'Agostino RB, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNulty KA, Wolf PA: Apolipoprotein E allele 4 is associated with dementia in the Framingham Study. *Neurology*. 1996; 46: 673-677
- 144 Lindpaintner K, Lee M, Larson MG, Rao VS, Pfeffer MA, Ordovas JM, et al. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. *N Engl J Med* 1996; 334:1023-1028
- 145 Meigs JB, Singer DE, Nathan DM, Cupples LA, **Wilson PWF**: Tracking of hemoglobin A_{1c} in the original cohort of the Framingham Heart Study *J. Clin. Epidemiol* 1996; 49: 411-417
- 146 Kannel WB, **Wilson PWF**: Homocysteine, folate, and vascular disease.(editorial) *J Myocardial Ischemia* 1996; 8: 60-63
- 147 Contois JH, McNamara JR, Lammi-Keefe CJ, **Wilson PWF**, Schaefer EJ: Reference Intervals for plasma apolipoprotein B as determined with a commercially available immunoturbidimetric Assay: Results from the Framingham Offspring Study *Clin. Chem.* 1996; 42: 515-523
- 148 Contois JH, McNamara JR, Lammi-Keefe CJ, **Wilson PWF**, Schaefer EJ: Reference intervals for plasma apolipoprotein A-I as Determined with a Commercially Available Immunoturbidimetric Assay: Results from the Framingham Offspring Study *Clin. Chem* 1996; 42: 507-514
- 149 **Wilson PWF**, Castelli WP: The Newer Coronary Risk Factors (chapter 10). Atlas of Heart Diseases ed E. Braunwald Volume X Atherosclerosis: Risk factors and treatment Brown,W.V. (Volume Editor) Mosby (St. Louis) 1996
- 150 **Wilson PWF**: Surrogate markers and prediction of cardiovascular disease (chapter 2) in Surrogate markers to assess efficacy of treatment in chronic liver disease. eds, Reichen R.E.. & Reichen J Kluwer 1996, pages 8-18
- 151 Boston AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, **Wilson PWF**, Schaefer EJ, Castelli WP: Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger: a prospective study. *JAMA* 1996; 276: 544-548
- 152 McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, **Wilson PWF**, Jacques P:Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study *Ann Intern Med* 1996; 125: 353-359
- 153 Kannel WB, **Wilson PWF**: Update on hyperlipidemia in the elderly: Is this a risk factor for heart disease? *Amer J Geriatric Cardiology* 1996; 5: 9
- 154 **Wilson PWF**, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. *Arteriosclerosis, Thrombosis and Vascular Biology* 1996; 16: 1250-1255

- 155 Siegel RD, Cupples A, Schaefer EJ, **Wilson PWF**: Dyslipidemia and Diabetes: The Framingham Offspring Study. *Metabolism* 1996; 45: 1267-1272
- 156 Li Z, McNamara JR, Fruchart J-C, Luc G, Bard JM, Ordovas JM, **Wilson PWF**, Schaefer EJ: Effects of gender, age and menopausal status on plasma lipoprotein subspecies and particle sizes *J Lipid Res* 1996; 37: 1886-1896
- 157 Tucker KL, Mahnken B, **Wilson PWF**, Jacques P, Selhub J: Folate fortification of the food supply: potential benefits and risks to the elderly population *JAMA* 1996; 276: 1879-1885
- 158 Contois JH, Lammi-Keefe CJ, McNamara JR, Vogel S, **Wilson PWF**, Schaefer EJ: Plasma lipoprotein (a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay *Clin Chim Acta* 1996; 253:21-35
- 159 Lamon-Fava S, **Wilson PWF**, Schaefer EJ: Body mass index and coronary heart disease risk factors in men and women: The Framingham Offspring Study *Arteriosclerosis, Thrombosis and Vascular Biology*. 1996; 16: 1509-1515
- 160 Welty FK, Mittleman MA, **Wilson PWF**, Sutherland PA, Matheney TH, Lipinska I, Muller JE, Levy D, Tofler GH: Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham Offspring Study. *Circulation* 1997; 95: 825-830
- 161 Kannel WB, **Wilson PWF**: Comparison of risk profiles for cardiovascular events: Implications for prevention. *Advances in Internal Medicine* 1997; 42: 39-66
- 162 **Wilson PWF**, Kannel WB: Should we measure lipoprotein(a)? (editorial) *Archives of Internal Medicine* 1997; 157: 1161-1162
- 163 Kiel DP, Myers RH, Cupples LA, Kong XF, Zhu XH, Ordovas J, Schaefer EJ, Felson DT, Rush D, **Wilson PWF**, Eisman JA, Holick MF: The BsmI vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density. *J Bone and Mineral Research* 1997; 12: 1049-1057
- 164 Murabito JM, D'Agostino RB, Silbershatz H, **Wilson PWF**: Intermittent Claudication: a risk profile from the Framingham Heart Study. *Circulation* 1997; 96: 44-49
- 165 Tucker K, Selhub J, **Wilson PWF**, Rosenberg I: Dietary intake pattern relates to plasma folate and homocysteine levels in the Framingham Heart Study. *J Nutr* 1996; 126: 3025-3031
- 166 Roubenoff R, Baumgartner RN, Kiel DP, Dallal GE, Hannan MT, Economos CD, Stauber PM, **Wilson PWF**, Harris TB: Application of bioelectrical impedance analysis to elderly populations. *J Gerontology A. Biol Sci Med Sci* 1997; 52: M129-136
- 167 Kannel WB, **Wilson PWF**: Relevance of dyslipidemia in the elderly. *ACC Current Journal Review* 1996 (Sept); 14-15
- 168 **Wilson PWF**, Hoeg JM, D'Agostino RB, Belanger AM, Silbershatz H, O'Leary D, Wolf PA: Cumulative Effects of Serum Cholesterol, Blood Pressure and Cigarette Smoking on Carotid Stenosis. *N Engl J Med* 1997; 337: 516-522
- 169 Kauppila LI, Polak J, Cupples LA, Hannan MT, Kiel DP, **Wilson PWF**: New indices to classify location, severity, and progression of calcific lesions in the abdominal aorta: a 25 year follow-up study. *Arteriosclerosis* 1997; 132: 245-250
- 170 Elias PK, Elias MF, D'Agostino RB, Cupples LA, **Wilson PWF**, Silbershatz H, Wolf PA: NIDDM and blood pressure as independent risk factor for poor cognitive performance. *Diabetes Care* 1997; 20: 1388-1395
- 171 Kauppila LI, McAlindon T, Evans S, **Wilson PWF**, Kiel D, Felson DT: Disc degeneration/back pain and calcification of the abdominal aorta. *Spine* 1997; 22: 1642-1647
- 172 Hiller R, Sperduto RB, Podgor MJ, **Wilson PWF**, Ferris III FL, Colton T, D'Agostino RB, Roseman MJ, Stockman ME, Milton RC: Cigarette Smoking and the risk of development of lens opacities *Arch Ophthalmol* 1997; 115: 1113-1118

- 173 Meigs, JB, D'Agostino, RB, Wilson, PWF., Cupples, LA, Nathan, DM, and Singer, DE. Risk variable clustering in the insulin resistance syndrome: The Framingham Offspring Study. *Diabetes* 1997; 46:1594-1600
- 174 **Wilson PWF**: An epidemiologic perspective on hypertension, ischemic heart disease, and heart failure. *Am J Cardiology* 1997; 80 (9B): 3J-8J
- 175 Vogel S, Contois JH, Tucker KL, **Wilson PWF**, Schaefer EJ, Lammi-Keefe CJ: Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study *Am J Clin Nutr* 1997; 66: 950-958
- 176 Levy D, **Wilson PWF**: Atherosclerotic Cardiovascular Disease : An epidemiologic perspective in Textbook of Cardiovascular Medicine, (ed Topol E): Lippincott-Raven 1997, p 13-30
- 177 Krall EA, Dawson-Hughes B, Hannan MT, **Wilson PWF**, Kiel DP: Postmenopausal estrogen replacement and tooth retention. *Am J Med* 1997; 102: 536-542
- 178 **Wilson PWF**: Newer metabolic risk factors for heart disease: A brief review. *Saudi Arabian Medical Journal* 1998; 18: 439-446
- 179 Roubenoff R, Harris TB, Abad LW, **Wilson PWF**, Dallal GE, Dinarello CA: Monocyte cytokine production in an elderly population: Effect of age and inflammation. *J Gerontology:Medical Sciences* 1998; 53A: M20-M26
- 180 **Wilson PWF**: An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. *Am J Cardiol* 1997; 80(9B): 3J-8J
- 181 **Wilson PWF**, Kannel WB: Clustering of risk factors, obesity, and syndrome X. *Nutrition in Clinical Care* 1998; 1(suppl 1): 44-50
- 182 Kannel WB, **Wilson PWF**, Silbershatz H, D'Agostino RB: Epidemiology of risk factor clustering in elevated blood pressure in Multiple Risk Factors in Cardiovascular Disease (ed Gotto Jr AM et al), 1998, (Kluwer, Netherlands) pp 325-333
- 183 Fleming DJ, Jacques PF, Dallal GE, Tucker KL, **Wilson PWF**, Wood RJ: Dietary determinants of iron stores in a free-living elderly population: The Framingham Heart Study *Am J Clin Nutr* 1998; 67: 722-733
- 184 Meigs JB, Nathan DM, **Wilson PWF**, Cupples LA, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: The Framingham Offspring Study. *Ann Intern Med* 1998; 128: 524-533
- 185 **Wilson PWF**, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. *Circulation* 1998; 97: 1837-1847
- 186 Ordovas JM, Cupples LA, **Wilson PWF**, Lahoz C, Levy D, Otvos JD, McNamara JR, Gagne E, Hayden M, Schaefer EJ: Advances in cardiovascular risk prediction: new biochemical and genetic markers. in Atherosclerosis XI (ed B. Jacotot, D. Mathe, J-C Fruchart) Elsevier Press (Singapore) 1998, pp 425-431
- 187 **Wilson PWF**, D'Agostino RB, Kannel WB: Secular trends in cardiovascular risk factor levels: a Framingham perspective. in Atherosclerosis XI ed B. Jacotot, D. Mathe, J-C Fruchart. Elsevier Press (Singapore) 1998, pp 659- 664
- 188 Visser M, Kiel DP, Langlois J, Hannan M, Felson DT, **Wilson PWF**, Harris TB: Muscle mass and fat mass in relation to bone mineral density in very old men and women: the Framingham Heart Study. *Applied Radiology and Isotopes* 1998; 49: 745-747
- 189 McNamara, J.R., Shah, P.K., Nakajima, K., Cupples, L.A., Wilson, P.W., Ordovas, J.M., and Schaefer, E.J. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. *Clinical Chemistry* 1998; 44:1224-1232
- 190 Hiller R, Podgor MJ, Sperduto RD, Nowroozi L, **Wilson PWF**, D'Agostino RB, Colton T, Framingham Eye Studies Group: A longitudinal study of body mass index and lens opacities: The Framingham Studies *Ophthalmology* 1998; 105: 1244-1250

- 191 Visser M, Harris TB, Hannan MT, Roubenoff R, Felson DT, **Wilson PWF**, Kiel DP: Body fat and skeletal muscle mass in relation to physical disability in vbery old men and women of the Framingham Heart Study. *J Gerontology* 1998; 53A: M214-M221
- 192 Fraenkel L, Zhang Y, Chaisson C, Evans S, **Wilson PWF**, Felson DT: The association of estrogen replacement therapy and Raynaud's phenomenon in post-menopausal women. *Annals of Internal Medicine* 1998; 129: 208-211
- 193 Kannel WB, **Wilson PWF**, Moser M, Rich MW: What older adults should know about high cholesterol. A position paper from the Society of Geriatric Cardiology. *American Journal of Geriatric Cardiology* 1998; 7: 43-44
- 194 **Wilson PWF**: Physical activity and CHD in Preventive Cardiology (ed Robinson K) Futura, New York, 1998, pp 51-67
- 195 **Wilson PWF**: Diabetes mellitus, insulin resistance and CHD in Preventive Cardiology (ed Robinson K) Futura, New York, 1998, pp 69-96
- 196 Kannel WB, **Wilson PWF**, D'Agostino RB, Cobb J: Sudden death in women *Amer Heart J* 1998; 136: 205-212
- 197 **Wilson PWF**: Do estrogens reduce glycemic levels? (editorial) *Diabetes Care* 1998; 21: 1585
- 198 Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. *Arthritis Rheum.* 1998; 41:1867-73.
- 199 Welty FK, Lahoz C, Tucker KL, Ordovas JM, **Wilson PW**, Schaefer EJ. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham Offspring population. *Arterioscler Thromb.Vasc.Biol.* 1998; 18: 1745-1751.
- 200 Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, **Wilson PWF**, Wright JT Jr.: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? *Am J Kidney Dis* 1998; 32: 853-906
- 201 **Wilson PW**, Culleton BF. Epidemiology of cardiovascular disease in the United States. *Am J Kidney Dis.* 1998; 32: S56-S65
- 202 **Wilson PW**. Diabetes mellitus and coronary heart disease. *Am J Kidney Dis.* 1998; 32: S89-100.
- 203 Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, **Wilson PWF**, Kiel DP. Association between insulin-like growth factor I and bone mineral density in older women and men The Framingham Heart Study. *J Clin Endocrinol Metab* 1998; 83: 4257-4262
- 204 Fleming DJ, Jacques PF, Dallal GE, Tucker KL, **Wilson PWF**, Wood RJ: Dietary determinants of iron stores in a free-living elderly population: The Framingham Heart Study. *Am J Clin Nutr* 1998; 67: 722-733
- 205 Culleton BF, **Wilson PWF**: Thrombogenic risk factors for cardiovascular disease in dialysis patients. *Seminars in Dialysis* 1999; 12: 117-125
- 206 Kannel WB, **Wilson PWF**, Larson MG, Evans JC: Coronary risk factors and coronary prevention in octogenarians in Cardiovascular Disease in the Octogenarian and Beyond (ed Wenger NK) Dunitz Press, 1999, pp 141-161

- 207 Haider AW, Larson MG, O'Donnell CJ, Evans JC, **Wilson PWF**, Levy D: The association of chronic cough with the risk of myocardial infarction: The Framingham Heart Study *Am J Med* 1999; 106: 279-284
- 208 Tucker KL, Chen H, Vogel S, **Wilson PWF**, Schaefer EJ, Lammi-Keefe CJ: Carotenoid intakes, assessed by dietary questionnaire, are associated with plasma carotenoid concentrations in an elderly population. *J Nutrition* 1999; 129: 438-445
- 209 Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, **Wilson PW**, Felson DT: Different factors influencing the expression of Raynaud's phenomenon in men and women. *Arthritis Rheum.* 1999; 42: 306-310
- 210 **Wilson PWF**, Kannel WB, Silbershatz H, D'Agostino R: Clustering of Metabolic Factors and Coronary Heart Disease. *Arch Intern Med* 1999; 159: 1104-1109
- 211 Bostom AG, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wolf PA, Rosenberg IH, **Wilson PWF**: Serum total homocysteine levels predict all cause and cardiovascular disease mortality in elderly Framingham men and women. *Arch Intern Med* 1999; 159: 1077-1080
- 212 Jacques PF, Selhub J, Bostom AG, **Wilson PWF**, Rosenberg IH: Impact of Folic Acid Fortification on Plasma Folate and Total Homocysteine Concentrations in Middle-Aged and Older Adults from the Framingham Study. *N Engl J Med* 1999; 340: 1449-1454
- 213 Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, **Wilson PWF**, Levy D: Profile for estimating risk of heart failure. *Arch Intern Med* 1999; 159: 1197-1204
- 214 Bostom AG, Rosenberg IH, Silbershatz, Jacques PF, Selhub J, D'Agostino RB, **Wilson PWF**, Wolf PA: Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. *Ann.Intern.Med.* 1999; 131: 352-355.
- 215 Culleton BF, Larson MG, Evans JC, **Wilson PWF**, Barrett BJ, Parfrey PS, Levy D: Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. *Arch.Intern.Med.* 1999; 159:1785-1790.
- 216 McAlindon TE, **Wilson PW**, Aliabadi P, Weissman B, Felson DT. Level of physical activity and the risk of radiographic and symptomatic knee osteoarthritis in the elderly: the Framingham Study. *Am.J Med.* 1999; 106:151-157.
- 217 Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara Jr, **Wilson PW**, Castelli WP, Ordovas JM, Schaefer EJ: Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. *Clin.Chem.* 1999; 45: 1039-1046.
- 218 Tucker KL, Hannan MT, Chen H, Cupples LA, **Wilson PW**, Kiel DP. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. *Am.J Clin.Nutr.* 1999; 69: 727-736.
- 219 **Wilson PW**. Metabolic risk factors for coronary heart disease: current and future prospects. *Curr.Opin.Cardiol.* 1999; 14: 176-185.

- 220 Kannel WB, **Wilson PWF**: Lipid control in the pre-statin era. in Statins: The HMG CoA Reductase Inhibitors in Perspective, (eds Gaw A, Packard CJ, Shepherd J) Dunitz Press, London, 1999, pp 21-34
- 221 **Wilson PWF**: From hypertension to heart failure: What have we learned? *Clin. Cardiol.* 1999; 22(suppl V); V1-V10
- 222 Culleton BF, Larson MG, **Wilson PWF**, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney Int.* 1999; 56: 2214-2219.
- 223 Guidry UC, Evans JC, Larson MG, **Wilson PWF**, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. *Circulation* 1999;100: 2054-2059.
- 224 Hiller R, Podgor MJ, Sperduto RD, **Wilson PWF**, Chew EY, D'Agostino RB. High intraocular pressure and survival: the Framingham Studies. *Am.J.Ophthalmol.* 1999;128: 440-445
- 225 Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, **Wilson PWF**, Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. *Arch.Intern.Med.* 1999; 159: 2206-2212.
- 226 Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, **Wilson PWF**: Hyperinsulinemia, hyperglycemia and impaired hemostasis: The Framingham Offspring Study *JAMA* 2000; 283: 221-228
- 227 D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, **Wilson PW**, Hartz SC: Primary and subsequent coronary risk appraisal: New results from The Framingham Study. *Am.Heart J.* 2000; 139: 272-281
- 228 Tucker KL, Rich S, Rosenberg I, Jacques P, Dallal G, **Wilson PW**, Selhub J: Plasma vitamin B-12 concentrations relate to intake source in the Framingham Offspring Study(1). *Am.J.Clin.Nutr.* 2000; 71: 514-522
- 229 Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman M, Muller JE, D'Agostino RB, **Wilson PW**, Levy D: Association of blood pressure with fibrinolytic potential in the Framingham Offspring Population. *Circulation* 2000; 101: 264-269
- 230 Couture P, Otvos JD, Cupples LA, **Wilson PW**, Schaefer EJ, Ordovas JM. Absence of association between genetic variation in the promoter of the microsomal triglyceride transfer protein gene and plasma lipoproteins in the Framingham Offspring Study. *Atherosclerosis* 1999; 148: 337-343.
- 231 Couture P, Otvos JD, Cupples LA, **Wilson PW**, Schaefer EJ, Ordovas JM. Association of the A-204C polymorphism in the cholesterol 7 α -hydroxylase gene with variations in plasma low-density lipoprotein cholesterol levels in the Framingham Offspring Study. *J.Lipid Res.* 1999; 40: 1883-9
- 232 Couture P, Otvos JD, Cupples LA, Lahoz Cm, **Wilson PWF**, Schaefer EJ, Ordovas JM: Association of the C-514T Polymorphism in the Hepatic Lipase Gene With Variations in Lipoprotein Subclass Profiles: The Framingham Offspring Study. *Arterioscler.Thromb.Vasc.Biol.* 2000; 20: 815-822
- 233 **Wilson PWF**: Emerging risk factors for coronary artery disease. Royal Society of Medicine Monograph Series (London) 1999; 258: pp 17-25

- 234 Fraenkel L, Tofler GH, Zhang H, Silbershatz H, D'Agostino RB, **Wilson PW**, Felson DT: The associations between plasma levels of von Willebrand factor and fibrinogen with Raynaud's phenomenon in men and women. *Am.J.Med.* 2000; 108: 583-586
- 235 Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, **Wilson PW**, Ordovas J, Schaefer EJ, Dawson-Hughes B, Kiel DP: Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. *Am.J.Clin.Nutr.* 2000; 71: 1201-1208.
- 236 Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, **Wilson PW**, Kiel DP. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study *J.Bone Miner.Res.* 2000; 15: 710-720.
- 237 Moore LL, Visioni AJ, **Wilson PW**, D'Agostino RB, Finkle WD, Ellison RC. Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus? *Epidemiology* 2000; 11: 269-273.
- 238 Shearman AM, Ordovas JM, Cupples LA, Schaefer EJ, Harmon MD, Shao Y, Keen,J.D.; DeStefano,A.L.; Joost,O.; Wilson,P.W.; Housman,D.E.; Myers,R.H.. Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32.3- qter: a genome-wide scan in the Framingham Study. *Hum.Mol.Genet.* 2000; 9: 1315-1320.
- 239 Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C; Coltell O; **Wilson PW**; Schaefer EJ: Association of Cholesteryl Ester Transfer Protein-TaqIB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk : The Framingham Study. *Arterioscler Thromb.Vasc.Biol.* 2000; 20: 1323-1329
- 240 **Wilson PWF**: The newer coronary risk factors in Atlas of Atherosclerosis: Risk Factors and Treatment (Second Edition) editor PWF Wilson, Current Science 2000 (Philadelphia, PA) 2000, pp 180-193
- 241 Kannel WB, **Wilson PWF**: Hypertension as a cardiovascular risk factor in Handbook of Hypertension, Volume 20: Epidemiology of Hypertension (ed C. J. Bulpitt) Elsevier Press (Amsterdam) 2000, pp 19-42
- 242 Meigs JB, Ordovas JM, Cupples LA, Singer DE, Nathan DM, Schaefer EJ, **Wilson PW**: Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. *Diabetes Care* 2000; 23: 669-674
- 243 **Wilson PWF**, Jacques PF: Epidemiology of homocysteine levels and relation to vitamins in *Homocysteine and Vascular Disease* (ed K. Robinson) Kluwer Academic Publishers (Amsterdam) 2000, pp 85-95
- 244 **Wilson PWF**: Homocysteine: The new risk factor for cardiovascular disease in the elderly. *Amer J Geriatric Cardiology* 2000; 9: 185-189
- 245 **Wilson PWF**: Lipids, lipases, and obesity: Does race matter? *Arterioscler.Thromb.Vasc.Biol* (editorial) 2000; 20: 1854-1856
- 246 Singh JP, Larson MG, O'Donnell CJ, **Wilson PF**, Tsuji H, Lloyd-Jones DM, Levy D: Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). *Am.J.Cardiol.* 2000; 86: 309-312
- 247 Sonnenberg LM, Quatromoni PA, Gagnon DR, Cupples LA, Franz MM, Ordovas JM, **Wilson PW**, Schaefer EJ, Millen BP: Diet and plasma lipids in women. II. Macronutrients and plasma triglycerides, high-density

- lipoprotein, and the ratio of total to high-density lipoprotein cholesterol in women: the Framingham nutrition studies. *J.Clin.Epidemiol.* 1996; 49: 665-72
- 248 Millen BE, Franz MM, Quatromoni PA, Gagnon DR, Sonnenberg LM, Ordovas JM, **Wilson PW**, Schaefer EJ, Cupples LA: Diet and plasma lipids in women. I. Macronutrients and plasma total and low-density lipoprotein cholesterol in women: the Framingham nutrition studies. *J.Clin.Epidemiol.* 1996; 49: 657-63
- 249 **Wilson PWF**, Benjamin EJ, Manolio TA: Workshop on nonvalvular atrial fibrillation in the elderly: Challenges for Prevention and Care *Am. J Geriatr. Cardiology* 2000;5; 73S-75S
- 250 Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, **Wilson PWF**, Muller JE, D'Agostino RB: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring population. *Circulation* 2000; 102: 1634-1638
- 251 Meigs JB, Cupples LA, **Wilson PWF**: Parental transmission of type 2 diabetes: The Framingham Offspring Study. *Diabetes* 2000; 49: 2201-2207
- 252 Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, **Wilson PW**, Felson DT: Association of Hypogonadism and Estradiol Levels with Bone Mineral Density in Elderly Men from the Framingham Study. *Ann.Intern.Med* 2000; 133: 951-963
- 253 Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley P, **Wilson PW**, D'Agostino RB, and Grinspoon S: Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy. *Clin.Infect.Dis.* 2001; 32:130-139
- 254 McNamara JR, Shah PK, Nakajima K, Cupples LA, **Wilson PW**, Ordovas JM, Schaefer EJ: Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. *Atherosclerosis* 2001; 154: 229-236
- 255 Gagne SE, Larson MG, Pimstone SN, Schaefer EJ, Kastelein JJ, **Wilson PW**, Ordovas JM, Hayden MR: A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. *Clin.Genet.* 1999; 55:450-454
- 256 **Wilson PW**: Lipoprotein measurements—setting priorities (editorial) *Am J Med* 2001; 110:71-72
- 257 **Wilson PWF**, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. *Circulation* 2001; 103: 1529-1534
- 258 Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB, **Wilson PWF**, Wood RJ: Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. *Am J Clin Nutr* 2001; 73: 638-646
- 259 Lloyd-Jones DM, O'Donnell CJ, Silbershatz H, D'Agostino RB, **Wilson PWF**: Applicability of cholesterol-lowering primary prevention trials to a general population. *Arch Intern Med* 2001; 161:949-954
- 260 Zee RYL, Myers RH, Hannan MT, **Wilson PWF**, Ordovas JM, Schaefer EJ, Lindpaintner K, Kiel DP: Absence of linkage for bone mineral density to chromosome 12q12-14 in the region of the vitamin D receptor gene. *Calcif. Tissue Int* 2000; 67: 434-439
- 261 Brousseau ME, Bodzioch M, Schaefer EJ, Goldkamp AL, Kielar D, Probst M, Ordovas JM, Aslanidis C, Lackner KJ, Rubins HB, Collins D, Robins SJ, **Wilson PWF**, Schmitz G: Common variants in the gene

- encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease *Atherosclerosis* 2001; 154: 607-611
- 262 **Wilson PWF**: Physical activity, fitness, and coronary risk estimation (editorial) *J. Cardiopulmonary Rehabilitation* 2001; 21:71-72
- 263 de Kleijn MJJ, van der Schouw YT, **Wilson PW**, Adlercreutz H, Mazur W, Grobbee DE, Jacques PF. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham Study. *J Nutr* 2001; 131:1826-1832
- 264 Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, **Wilson PWF**. Bone loss and progression of abdominal aortic calcification over a 25-year period: The Framingham Heart Study. *Calcif.Tissue Int* 2001; 68; 271-276
- 265 Hadigan C, Meigs JB, Rabe J, D'Agostino RB, **Wilson PW**, Lipinska I, Tofler GH, Grinspoon SS. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. *J Clin Endocrinol Metab* 2001; 86: 939-943
- 266 Jacques PF, Bostom AG, **Wilson PW**, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. *Am J Clin Nutr* 2001; 73: 613-621
- 267 Lahoz C, Schaefer EJ, Cupples LA, **Wilson PW**, Levy D, Osgood D, Parpos S, Pedro-Botet S, Daly JA, Ordovas JM. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. *Atherosclerosis* 2001; 154: 529-537
- 268 Corella D, Tucker K, Lahoz C, Coltell O, Cupples LA, **Wilson PW**, Schaefer EJ, Ordovas JM. Alcohol drinking determines the effect of the APOE locus on LDL- cholesterol concentrations in men: the Framingham Offspring Study. *Am J Clin Nutr* 2001; 73:736-745
- 269 Friso S, Jacques PF, **Wilson PW**, Rosenberg IH, Selhub J. Low circulating vitamin B₆ is associated with elevation of the inflammation marker c-reactive protein independently of plasma homocysteine levels. *Circulation* 2001; 103:2788-2791
- 270 Galluzzi JR, Cupples LA, Meigs JB, **Wilson PW**, Schaefer EJ, Ordovas JM: Association of the Ala54-thr Polymorphism in the Intestinal Fatty Acid-Binding Protein With 2-h Postchallenge Insulin Levels in the Framingham Offspring Study. *Diabetes Care* 2001; 24:1161-1166
- 271 D'Agostino, RB Sr., Grundy S, Sullivan LM, **Wilson P**: Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation. *JAMA* 2001; 286:180-187
- 272 Grundy SM, D'Agostino RB Sr, Mosca L, Burke GL, **Wilson PW**, Rader DJ, Cleeman JI, Roccella EJ, Cutler EA, Friedman LM: Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. *Circulation* 2001; 104: 491-496
- 273 Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, **Wilson PW**, Lahoz C, Cucinotta D, Couture P, Mallory T, Schaefer EJ, Ordovas JM: Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham Offspring Study. *Atherosclerosis* 2001;158:173-81.
- 274 Worzala K, Hiller R, Sperduto RD, Mutalik K, Murabito JM, Moskowitz M, D'Agostino RB, **Wilson PW**: Postmenopausal estrogen use, type of menopause, and lens opacities: the Framingham studies. *Arch.Intern.Med* 2001;161:1448-54.
- 275 Meigs JB, Haffner SM, Nathan DM, D'Agostino RB, **Wilson PW**: Sample exchange to compare insulin measurements between the San Antonio Heart Study and the Framingham Offspring Study. *J Clin Epidemiol.* 2001; 54:1031-1036
- 276 Mukamal KJ, Jadhav PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, **Wilson PW**, Ellison RC, Silbershatz H, Muller JE, Tofler GH: Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. *Circulation* 2001; 104:1367-1373
- 277 Haveman-Nies A, Tucker KL, de Groot LC, Wilson, van Staveren WA: Evaluation of dietary quality in relationship to nutritional and lifestyle factors in elderly people of the US Framingham Heart Study and the European SENECA Study. *Eur.J Clin Nutr* 2001; 55: 870-880, 2001.

- 278 Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, **Wilson PW**: Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study. *Stroke* 2001; 32: 2575-2579, 2001.
- 279 Thompson G, Dean J, **Wilson PWF**: Dyslipidaemia in Clinical Practice. Martin Dunitz, London 2002
- 280 Seshadri S, Wolf PA, Beiser A, Vasan RS, **Wilson PW**, Kase CS, Kelly-Hayes M, Kannel WB and D'Agostino RB: Elevated midlife blood pressure increases stroke risk in elderly persons: the Framingham Study. *Arch.Intern Med* 2001; 161: 2343-2350
- 281 Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, **Wilson PW**: Family breast cancer history and mammography: Framingham Offspring Study. *Am J Epidemiol.* 2001; 154: 916-923
- 282 **Wilson PWF**: Diabetes Mellitus and Coronary Heart Disease. *Endocrinology and Metabolism Clinics of North America* 2001; 30: 857-882
- 283 Vasan RS, Massaro JM, **Wilson PW**, Seshadri S, Wolf PA, Levy D, D'Agostino RB: Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study. *Circulation* 2002; 105:48-53
- 284 Ordovas JM, Corella D, Cupples LA, Demissie S, Kelleher A, Coltell O, **Wilson PW**, Schaefer EJ, Tucker K: Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. *Am J Clin Nutr* 2002; 75:38-46
- 285 Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, **Wilson PW**, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N.Engl.J Med* 2002; 346: 476-483
- 286 Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, **Wilson PW**, Rosenberg IH, Selhub J: The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. *J Nutr* 2002; 132: 283-288
- 287 de Kleijn MJ, van der Schouw YT, **Wilson PW**, Grobbee DE, Jacques PF: Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S.women: the Framingham Study. *J Nutr* 2002; 132:276-282
- 288 Meigs JB, Panhuysen CI, Myers RH, **Wilson PW**, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. *Diabetes* 2002; 51:833-840.
- 289 **Wilson PW**, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. *Am J Geriatr Cardiol* 2002; 11:119-123
- 290 Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D'Agostino RB, Sr., and **Wilson PW**. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. *Diabetes Care* 2001; 24:1403-1410
- 291 de Kleijn MJ, van der Schouw YT, **Wilson PW**, Grobbee DE, Jacques PF. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S.women: The Framingham Study. *J Nutr* 2002; 132: 276-282
- 292 Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, **Wilson PW** et al. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. *J Nutr* 2002; 132: 283-288
- 293 Meigs JB, D'Agostino RB, Sr., Nathan DM, Rifai N, **Wilson PW**. Longitudinal Association of Glycemia and Microalbuminuria: The Framingham Offspring Study. *Diabetes Care* 2002; 25: 977-983
- 294 Meigs JB, Panhuysen CI, Myers RH, **Wilson PW**, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. *Diabetes* 2002; 51:833-840
- 295 McKeown NM, Jacques PF, Gundberg CM, Peterson JW, Tucker KL, Kiel DP, **Wilson PW**, Booth SL. Dietary and nondietary determinants of vitamin K biochemical measures in men and women. *J Nutr* 2002; 132:1329-1334

- 296 Redberg RF, Greenland P, Fuster V, Pyorala K, Blair SN, Folsom AR, Newman AB, O'Leary DH, Orchard TJ, Psaty B, Schwartz JS, Starke R, **Wilson PW**. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group III: risk assessment in persons with diabetes. *Circulation* 2002; 105:e144-e152
- 297 Tai ES, Demissie S, Cupples LA, Corella D, **Wilson PW**, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. *Arterioscler Thromb Vasc Biol* 2002; 22:805-810
- 298 Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, **Wilson PW**. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. *Diabetes Care* 2002; 25:989-994
- 299 Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, **Wilson PW**: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. *Am.Heart J.* 2002; 143:961-965
- 300 Tucker KL, Chen H, Hannan MT, Cupples LA, **Wilson PW**, Felson D, Kiel DP: Bone mineral density and dietary patterns in older adults: the Framingham Osteoporosis Study. *Am.J.Clin.Nutr.* 2002; 76:245-252
- 301 Vargas-Martinez C, Ordovas JM, **Wilson PW**, Selhub J: The glutamate carboxypeptidase gene II (C>T) polymorphism does not affect folate status in the Framingham Offspring cohort. *J.Nutr.* 2002; 132:1176-1179
- 302 Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME, Nathan DM, **Wilson PW**, O'Donnell CJ. Coronary Artery Calcification in Type 2 Diabetes and Insulin Resistance: The Framingham Offspring Study. *Diabetes Care* 2002; 25:1313-1319.
- 303 McKeown NM, Meigs JB, Liu S, **Wilson PW**, Jacques PF. Whole-grain intake is favorably associated with metabolic risk factors for type 2 diabetes and cardiovascular disease in the Framingham Offspring Study. *Am J Clin Nutr* 2002; 76:390-398
- 304 Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, **Wilson PW**, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. *Am J Cardiol* 2002; 90:254-258
- 305 O'Donnell CJ, Chazaro I, **Wilson PW**, Fox C, Hannan MT, Kiel DP, Cupples LA. Evidence for heritability of abdominal aortic calcific deposits in the Framingham Heart Study. *Circulation* 2002; 106:337-341
- 306 Kenchaiah S, Evans JC, Levy D, **Wilson PW**, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. *N.Engl.J.Med.* 2002; 347:305-313
- 307 Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, Clouse ME, D'Agostino RB, **Wilson PW**, O'Donnell CJ. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. *Circulation* 2002; 106:1189-1191
- 308 **Wilson P.W.F.** Homocysteine, vitamins and coronary artery disease. In: Braunwald E, editor. *Harrison's Advances in Cardiology*. New York: McGraw-Hill, 2002: 18-23
- 309 **Wilson PW**, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch Intern Med* 2002; 162:1867-1872
- 310 Choumenkovitch SF, Selhub J, **Wilson PW**, Rader JI, Rosenberg IH, Jacques PF. Folic Acid Intake from Fortification in United States Exceeds Predictions. *J Nutr* 2002; 132:2792-2798
- 311 Karasik D, Rosen CJ, Hannan MT, Broe KE, Dawson-Hughes B, Gagnon DR, **Wilson PW**, Visser M, Langlois JA, Mohan S, Kiel DP. Insulin-Like Growth Factor Binding Proteins 4 and 5 and Bone Mineral Density in Elderly Men and Women. *Calcif Tissue Int* 2002; 71: 323-328
- 312 Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, **Wilson PW**, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. *JAMA* 2002; 288:1252-1259.
- 313 Meigs JB, Nathan DM, D'Agostino RB, Sr., **Wilson PW**: Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk: The Framingham Offspring Study. *Diabetes Care* 2002; 25:1845-1850
- 314 Ordovas JM, Corella D, Demissie S, Cupples LA, Couture P, Coltell O, **Wilson PW**, Schaefer EJ, Tucker KL. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene

- promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. *Circulation* 2002; 106:2315-2321
- 315 Haider AW, **Wilson PW**, Larson MG, Evans JC, Michelson EL, Wolf PA, O'Donnell CJ, Levy D. The association of seropositivity to *Helicobacter pylori*, *Chlamydia pneumoniae*, and cytomegalovirus with risk of cardiovascular disease. A prospective study. *J Am Coll Cardiol* 2002; 40:1408-1413
- 316 **Wilson PW**. Homocysteine and coronary heart disease: how great is the hazard? *JAMA* 2002; 288:2042-2043
- 317 **Wilson PW**. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *Curr Cardiol Rep* 2002; 4:486
- 318 **Wilson PW**. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Curr Cardiol Rep* 2002; 4:486-487
- 319 **Wilson PW**. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. *Curr Cardiol Rep* 2002; 4:485
- 320 Wang TJ, Nam BH, **Wilson PW**, Wolf PA, Levy D, Polak JF, D'Agostino RB, O'Donnell CJ. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol* 2002; 22:1662-1667
- 321 Walsh CR, Cupples LA, Levy D, Kiel DP, Hannan M, **Wilson PW**, O'Donnell CJ. Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study. *Am Heart J* 2002; 144:733-739
- 322 Kannel WB, **Wilson PW**, Nam BH, D'Agostino RB. Risk stratification of obesity as a coronary risk factor. *Am J Cardiol* 2002; 90:697-701
- 323 Fleming DJ, Tucker KL, Jacques PF, Dallal GE, **Wilson PW**, Wood RJ. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. *Am J Clin Nutr* 2002; 76:1375-1384
- 324 Tofler GH, D'Agostino RB, Jacques PF, Bostom AG, **Wilson PW**, Lipinska I, Mittleman MA, Selhub J. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. *Thromb Haemost* 2002; 88:799-804
- 325 Atwood LD, Heard-Costa NL, Cupples LA, Jaquish CE, **Wilson PW**, D'Agostino RB. Genomewide Linkage Analysis of Body Mass Index across 28 Years of the Framingham Heart Study. *Am J Hum Genet* 2002; 71:1044-1050
- 326 Booth SL, Broe KE, Gagnon DR, Tucker KL, Hannan MT, McLean RR, Dawson-Hughes B, **Wilson PW**, Cupples LA, Kiel DP. Vitamin K intake and bone mineral density in women and men. *Am J Clin Nutr* 2003; 77:512-516
- 327 **Wilson PW**. Lower diabetes risk with hormone replacement therapy: an encore for estrogen? *Ann Intern Med* 2003; 138:69-70
- 328 Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, **Wilson PW**, Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. *Circulation* 2003; 107:448-454
- 329 Freitag MH, Larson MG, Levy D, Benjamin EJ, Wang TJ, Leip EP, **Wilson PW**, Vasan RS. Plasma Brain Natriuretic Peptide Levels and Blood Pressure Tracking in the Framingham Heart Study. *Hypertension* 2003; 41: 978-983
- 330 Hiller R, Sperduto RD, Reed GF, D'Agostino RB, **Wilson PW**. Serum lipids and age-related lens opacities: a longitudinal investigation: the Framingham Studies. *Ophthalmology* 2003; 110:578-583
- 331 Keaney JF, Jr., Larson MG, Vasan RS, **Wilson PW**, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. *Arterioscler Thromb Vasc Biol* 2003; 23:434-439
- 332 Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, **Wilson PW**. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. *JAMA* 2003; 289:1251-1257

- 333 McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, **Wilson PW**, D'Agostino RB, O'Donnell CJ, Patel DD, Murphy PM. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. *J Clin Invest* 2003; 111:1241-1250
- 334 Vasani RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, **Wilson PW**, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. *Circulation* 2003; 107:1486-1491
- 335 Hadigan C, Meigs JB, **Wilson PW**, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. *Clin Infect Dis* 2003; 36:909-916
- 336 Keaney JF, Jr., Larson MG, Vasani RS, **Wilson PW**, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. *Arterioscler Thromb Vasc Biol* 2003; 23:434-439
- 337 Osgood D, Corella D, Demissie S, Cupples LA, **Wilson PW**, Meigs JB, Schaefer EJ, Coltell O, Ordovas JM. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham Study. *J Clin Endocrinol Metab* 2003; 88:2869-2879
- 338 Tan ZS, Seshadri S, Beiser A, **Wilson PW**, Kiel DP, Tocco M, D'Agostino RB, Wolf PA. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. *Arch Intern Med* 2003; 163:1053-1057
- 339 Panhuysen CI, Cupples LA, **Wilson PW**, Herbert AG, Myers RH, Meigs JB. A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study. *Diabetologia* 2003; 46:579-587
- 340 Wang TJ, Nam BH, D'Agostino RB, Wolf PA, Lloyd-Jones DM, MacRae CA, **Wilson PW**, Polak JF, O'Donnell CJ. Carotid Intima-Media Thickness Is Associated With Premature Parental Coronary Heart Disease. The Framingham Heart Study. *Circulation* 2003; 108: 572-576
- 341 **Wilson PW**, Smith SC, Jr., Blumenthal RS, Burke GL, Wong ND. 34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging? *J Am Coll Cardiol* 2003; 41:1898-1906
- 342 Pasternak RC, Abrams J, Greenland P, Smaha LA, **Wilson PW**, Houston-Miller N. 34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap? *J Am Coll Cardiol* 2003; 41:1863-1874
- 343 Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, **Wilson PW**. American College of Endocrinology position statement on the insulin resistance syndrome. *Endocr Pract* 2003; 9:237-252
- 344 Payette H, Roubenoff R, Jacques PF, Dinarello CA, **Wilson PW**, Abad LW, Harris T. Insulin-Like Growth Factor-1 and Interleukin 6 Predict Sarcopenia in Very Old Community-Living Men and Women: The Framingham Heart Study. *J Am Geriatr Soc* 2003; 51:1237-1243
- 345 **Wilson PW**, Smith SC, Jr., Blumenthal RS, Burke GL, Wong ND. 34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging? *J Am Coll Cardiol* 2003; 41: 1898-1906
- 346 Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, **Wilson PW**. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. *JAMA* 2003; 290: 891-897
- 347 Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, **Wilson PW**. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. *Arch Intern Med* 2003; 163:1939-1942
- 348 Lloyd-Jones DM, **Wilson PW**, Larson MG, Leip E, Beiser A, D'Agostino RB et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. *Arch Intern Med* 2003; 163:1966-1972

- 349 **Wilson PW**, Grundy SM. The metabolic syndrome: practical guide to origins and treatment: Part I *Circulation* 2003; 108:1422-1424, Part II *Circulation* 2003; 108:1537-1540
- 350 **Wilson PW**. The antihypertensive and lipid-lowering treatment to prevent heart attack trial: modest effects on lipids and heart disease. *Curr Cardiol Rep* 2003; 5:461
- 351 **Wilson PW**. The anglo-scandinavian cardiac outcomes trial lipid-lowering arm: significant lipid and coronary heart disease effects. *Curr Cardiol Rep* 2003; 5:462
- 352 Roubenoff R, Parise H, Payette HA, Abad LW, D'Agostino R, Jacques PF et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. *Am J Med* 2003; 115:429-435
- 353 Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. *Ann Intern Med* 2003; 139:642-648
- 354 Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, **Wilson PW**. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 2003; 108:2154-2169. also in *Hypertension* 2003; 42:1050-1065
- 355 Russo GT, Friso S, Jacques PF, Rogers G, Cucinotta D, **Wilson PW**, Ordovas JM, Rosenberg IH, Selhub J. Age and Gender Affect the Relation between Methylenetetrahydrofolate Reductase C677T Genotype and Fasting Plasma Homocysteine Concentrations in the Framingham Offspring Study Cohort. *J Nutr* 2003; 133: 3416-3421
- 356 Lin JP, Cupples LA, **Wilson PW**, Heard-Costa N, O'Donnell CJ. Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham Study. *Am J Hum Genet* 2003; 72:1029-1034
- 357 Janardhan V, Wolf PA, Kase CS, Massaro JM, D'Agostino RB, Franzblau C, **Wilson PW**. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and Offspring Study. *Stroke* 2004; 35:736-741
- 358 McKeown NM, Meigs JB, Liu S, Saltzman E, **Wilson PW**, Jacques PF: Carbohydrate Nutrition, Insulin Resistance, and the Prevalence of the Metabolic Syndrome in the Framingham Offspring Cohort. *Diabetes Care* 2004; 27:538-546
- 359 Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, **Wilson PW**, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. *Circulation* 2004; 109:594-600
- 360 Fox CS, Larson MG, Leip EP, Culleton B, **Wilson PW**, Levy D. Predictors of new-onset kidney disease in a community-based population. *JAMA* 2004; 291:844-850
- 361 Samelson EJ, Cupples LA, Hannan MT, **Wilson PW**, Williams SA, Vaccarino V, Zhang Y, Kiel DP. Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study. *Bone* 2004; 34:557-561
- 362 Samelson EJ, Kiel DP, Broe KE, Zhang Y, Cupples LA, Hannan MT, **Wilson PW**, Levy D, Williams SA, Vaccarino V. Metacarpal cortical area and risk of coronary heart disease: the Framingham Study. *Am J Epidemiol* 2004; 159:589-595
- 363 Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, **Wilson PW**. Relations of Serum Aldosterone to Cardiac Structure. Gender-Related Differences in the Framingham Heart Study. *Hypertension* 2004; 43: 957-962
- 364 Fox CS, Heard-Costa NL, **Wilson PW**, Levy D, D'Agostino RB, Sr., Atwood LD. Genome-Wide Linkage to Chromosome 6 for Waist Circumference in the Framingham Heart Study. *Diabetes* 2004; 53:1399-1402
- 365 Fox CS, Sullivan L, D'Agostino RB, Sr., **Wilson PW**. The Significant Effect of Diabetes Duration on Coronary Heart Disease Mortality: The Framingham Heart Study. *Diabetes Care* 2004; 27:704-708

- 366 Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, D'Agostino RB, **Wilson PW**, Schaefer EJ. Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study. *Clin Chem* 2004; 50: 1189-1200
- 367 Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R, Jr., Levin A, Masri B, Parekh R, Wanner C, Wheeler DC, **Wilson PW**. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. *Am J Transplant* 2004; 4 Suppl 7:13-53
- 368 Murabito JM, Nam BH, D'Agostino RB, Sr., Lloyd-Jones DM, O'Donnell CJ, **Wilson PW**. Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. *Ann Intern Med* 2004; 140:434-440
- 369 Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, **Wilson PW**, Levy D, Muller JE, Tofler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. *Thromb Haemost* 2004; 91:683-689
- 370 Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, Rosenberg IH, Levy D, **Wilson PW**, Vasan RS. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. *Eur Heart J* 2004; 25:523-530
- 371 Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, **Wilson PW**. Relations of Serum Aldosterone to Cardiac Structure. Gender-Related Differences in the Framingham Heart Study. *Hypertension* 2004; 43: 957-962
- 372 Haider AW, Roubenoff R, **Wilson PW**, Levy D, D'Agostino R, Silbershatz H, O'Donnell CJ. Monocyte cytokine production, systemic inflammation and cardiovascular disease in very elderly men and women: The Framingham Heart Study. *Eur J Cardiovasc Prev Rehabil* 2004; 11:214-215
- 373 Liu J, Hong Y, D'Agostino RB, Sr., Wu Z, Wang W, Sun J, **Wilson PW**, Kannel WB, Zhao D. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. *JAMA* 2004; 291:2591-2599
- 374 Meigs JB, Williams K, Sullivan LM, Hunt KJ, Haffner SM, Stern MP, Gonzalez VC, Perhanidis JS, Nathan DM, D'Agostino RB, Jr., D'Agostino RB, Sr., **Wilson PW**. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. *Diabetes Care* 2004; 27:1417-1426
- 375 Lloyd-Jones DM, Nam BH, D'Agostino RB, Sr., Levy D, Murabito JM, Wang TJ, **Wilson PW**, O'Donnell CJ. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. *JAMA* 2004; 291:2204-2211
- 376 **Wilson PWF**: Assessing coronary heart disease risk with traditional and novel risk factors. *Clin Cardiol* 2004; 27 (Suppl III); 7-11
- 377 Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, **Wilson PW**, Vasan RS. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. *Circulation* 2004; 109:2850-2856
- 378 Smith SC, Jr., Milani RV, Arnett DK, Crouse JR, III, McDermott MM, Ridker PM, Rosenson RS, Taubert KA, **Wilson PW**. Atherosclerotic vascular disease conference: Writing Group II: risk factors. *Circulation* 2004; 109:2613-2616
- 379 Ridker PM, **Wilson PW**, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? *Circulation* 2004; 109:2818-2825
- 380 Kannel WB, D'Agostino RB, Sullivan L, **Wilson PW**. Concept and usefulness of cardiovascular risk profiles. *Am Heart J* 2004; 148:16-26
- 381 Lloyd-Jones DM, **Wilson PW**, Larson MG, Beiser A, Leip EP, D'Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. *Am J Cardiol* 2004; 94:20-24

- 382 Vasan RS, Evans JC, Larson MG, **Wilson PW**, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. *N Engl J Med* 2004; 351:33-41
- 383 Keaney JF, Jr., Massaro JM, Larson MG, Vasan RS, **Wilson PW**, Lipinska I, Corey D, Sutherland P, Vita JA, Benjamin EJ. Heritability and correlates of intercellular adhesion molecule-1 in the Framingham Offspring Study. *J Am Coll Cardiol* 2004; 44:168-173
- 384 Kannel WB, **Wilson PW**, Nam BH, D'Agostino RB, Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. *Am J Cardiol* 2004; 94:380-384
- 385 Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., **Wilson PW**. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. *Circulation* 2004; 110:380-385
- 386 **Wilson PW**. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. *Endocrinol Metab Clin North Am* 2004; 33:467-481
- 387 **Wilson PW**. Framingham and European risk algorithms: implications for African Americans. *Rev Cardiovasc Med* 2004; 5 Suppl 3:S34-S41
- 388 **Wilson PW**. Coronary atherosclerosis progression by intravascular ultrasound with intensive versus moderate lipid lowering. *Curr Cardiol Rep* 2004; 6:437-438
- 389 **Wilson PW**. Recombinant apolipoprotein a-I milano effects on coronary atherosclerosis. *Curr Cardiol Rep* 2004; 6:438
- 390 Booth SL, Broe KE, Peterson JW, Cheng DM, Dawson-Hughes B, Gundberg CM, Cupples LA, **Wilson PW**, Kiel DP. Associations between Vitamin K Biochemical Measures and Bone Mineral Density in Men and Women. *J Clin Endocrinol Metab* 2004; 89:4904-4909
- 391 Meigs JB, Dupuis J, Herbert AG, Liu C, **Wilson PW**, Cupples LA. The Insulin Gene Variable Number Tandem Repeat and Risk of Type 2 Diabetes in a Population-Based Sample of Families and Unrelated Men and Women. *J Clin Endocrinol Metab* 2004; 90: 1137-1143
- 392 Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, **Wilson PW**, Vasan RS. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study. *Eur Heart J* 2004; 25:1509-1516
- 393 Fox CS, Yang Q, Cupples LA, Guo CY, Larson MG, Leip EP, **Wilson PW**, Levy D. Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. *J Am Soc Nephrol* 2004; 15:2457-2461
- 394 Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB, Sr., **Wilson PW**, Savage PJ. Trends in cardiovascular complications of diabetes. *JAMA* 2004; 292:2495-2499
- 395 Vita JA, Keaney JF, Jr., Larson MG, Keyes MJ, Massaro JM, Lipinska I, Lehman BT, Fan S, Osypiuk E, **Wilson PW**, Vasan RS, Mitchell GF, Benjamin EJ. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. *Circulation* 2004; 110:3604-3609
- 396 **Wilson PWF**: The epidemiology of atherosclerotic disease. Chapter 2 in *Molecular mechanisms of atherosclerosis*, ed. J Loscalzo, 2005 Taylor & Francis (London), pp 3-28
- 397 Vita JA, Keaney JF, Jr., Larson MG, Keyes MJ, Massaro JM, Lipinska I, Lehman BT, Fan S, Osypiuk E, **Wilson PW**, Vasan RS, Mitchell GF, Benjamin EJ. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. *Circulation* 2004; 110:3604-3609
- 398 **Wilson PW**. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. *Circulation* 2004; 110:e568-e571
- 399 Braam L, McKeown N, Jacques P, Lichtenstein A, Vermeer C, **Wilson P**, Booth S. Dietary phylloquinone intake as a potential marker for a heart-healthy dietary pattern in the Framingham Offspring cohort. *J Am Diet Assoc* 2004; 104:1410-1414
- 400 Fortmann SP, Ford E, Criqui MH, Folsom AR, Harris TB, Hong Y, Pearson TA, Siscovick D, Vinicor F, **Wilson PF**. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to

- Clinical and Public Health Practice: report from the population science discussion group. *Circulation* 2004; 110:e554-e559
- 401 Fox CS, Yang Q, Guo CY, Cupples LA, **Wilson PW**, Levy D et al. Genome-wide linkage analysis to urinary microalbuminuria in a community-based sample: The Framingham Heart Study. *Kidney Int.* 2005;67:70-4
- 402 Cendoroglo MS, Lahoz C, Martinez TL, Ordovas JM, Lamon-Fava S, Cupples LA, **Wilson PW**, Schaefer EJ. Association of apo A-IV 360 (Gln --> His) polymorphism with plasma lipids and lipoproteins: the Framingham Offspring Study. *Atherosclerosis* 2005; 179:169-175
- 403 Nanchahal K, Morris JN, Sullivan LM, **Wilson PW**. Coronary heart disease risk in men and the epidemic of overweight and obesity. *Int J Obes Relat Metab Disord* 2005; 29:317-323
- 404 Meigs JB, Dupuis J, Herbert AG, Liu C, **Wilson PW**, Cupples LA. The insulin gene variable number tandem repeat and risk of type 2 diabetes in a population-based sample of families and unrelated men and women. *J Clin Endocrinol Metab* 2005; 90:1137-1143
- 405 Yang Q, Lai CQ, Parnell L, Cupples LA, Adiconis X, Zhu Y, **Wilson PW**, Housman DE, Shearman AM, D'Agostino RB, Ordovas JM. Genome-wide linkage analyses and candidate gene fine mapping for HDL3 cholesterol: the Framingham Study. *J Lipid Res* 2005; 46: 1416-1425
- 406 Vasan RS, Sullivan LM, **Wilson PW**, Sempos CT, Sundstrom J, Kannel WB, Levy D, D'Agostino RB. Relative importance of borderline and elevated levels of coronary heart disease risk factors. *Ann Intern Med* 2005; 142: 393-402
- 407 Murabito JM, Yang Q, Fox C, **Wilson PW**, Cupples LA. Heritability of Age at Natural Menopause in the Framingham Heart Study. *J Clin Endocrinol Metab* 2005; 90: 3427-3430
- 408 Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, **Wilson PW**, Rifai N, Meigs JB, Ricken G, Lifton RP, Levy D, Vasan RS. Clinical and Genetic Correlates of Serum Aldosterone in the Community: The Framingham Heart Study. *Am J Hypertens* 2005; 18:657-665
- 409 Herbert A, Liu C, Karamohamed S, Schiller J, Liu J, Yang Q, **Wilson PW**, Cupples LA, Meigs JB. The -174 IL-6 GG genotype is associated with a reduced risk of type 2 diabetes mellitus in a family sample from the National Heart, Lung and Blood Institute's Framingham Heart Study. *Diabetologia* 2005; 48:1492-1495
- 410 Erkkila AT, Lichtenstein AH, Jacques PF, Hu FB, **Wilson PW**, Booth SL. Determinants of plasma dihydrophyloquinone in men and women. *Br J Nutr* 2005; 93:701-708
- 411 Djousse L, Levy D, Herbert AG, **Wilson PW**, D'Agostino RB, Cupples LA, Karamohamed S, Ellison RC. Influence of Alcohol Dehydrogenase 1C Polymorphism on the Alcohol-Cardiovascular Disease Association (from the Framingham Offspring Study). *Am J Cardiol* 2005; 96:227-232
- 412 Rother J, Steg PG, Ohman EM, Bhatt DL, **Wilson PW**. Atherothrombosis and Stroke - A Lot More to Know! *Cerebrovasc Dis* 2005; 20:139-140
- 413 **Wilson PWF**. The newer coronary risk factors in Atlas of Atherosclerosis, Fourth Edition (ed Grundy S) *Current Medicine* 2005, pp 169-185
- 414 Meigs JB, **Wilson PWF**, Goldberg IJ, Semenkovich CF, Ginsberg HN. Diabetes mellitus and vascular disease risk in Atlas of Atherosclerosis, Fourth Edition (ed Grundy S) *Current Medicine* 2005, pp 214-233
- 415 **Wilson PWF**. Atherosclerosis: Risk factors and treatment in Essential Atlas of Heart Diseases, Third Edition. (ed Braunwald, E), *Current Medicine* 2005, pp 1-24
- 416 Murabito JM, Evans JC, D'Agostino RB, Sr., **Wilson PW**, Kannel WB. Temporal Trends in the Incidence of Intermittent Claudication from 1950 to 1999. *Am J Epidemiol* 2005; 162: 1-8
- 417 Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Thompson SG, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, **Wilson PW**, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriguez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Coll E, Marchioli R, Valagussa F,

- Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Iso H, Salomaa V, Harald K, Rasi V, Vahtera E, Jousilahti P, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben Shlomo Y, Davey SG, Palmieri V, Yeh JL, Meade TW, Rudnicka A, Knottenbelt C, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. *JAMA* 2005; 294:1799-1809
- 418 **Wilson PW**. Cardiac rehabilitation and getting to lipid goals. *J Cardiopulm Rehabil* 2005; 25:264-265
- 419 **Wilson PW**. Estimating the risk for atherothrombosis: are current approaches sufficient? *Eur J Cardiovasc Prev Rehabil* 2005; 12:427-432
- 420 Murabito JM, Yang Q, Fox C, **Wilson PW**, Cupples LA. Heritability of Age at Natural Menopause in the Framingham Heart Study. *Obstet Gynecol Surv* 2005; 60:656-657
- 421 Fox CS, Larson MG, Leip EP, Meigs JB, **Wilson PW**, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. *Diabetes Care* 2005; 28:2436-2440
- 422 Dupuis J, Larson MG, Vasan RS, Massaro JM, **Wilson PW**, Lipinska I, Corey D, Vita JA, Keaney JF, Jr., Benjamin EJ. Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: Evidence for susceptibility loci on 1q. *Atherosclerosis* 2005; 182:307-314
- 423 **Wilson PW**. Treatment to New Targets Trial Results: Lower LDL-C is better for the heart. *Curr Cardiol Rep* 2005; 7:443-444
- 424 **Wilson PW**. Testing Whether Lower Low-density Lipoprotein Cholesterol or C-reactive Protein Really Determines Lower Risk for Heart Disease. *Curr Cardiol Rep* 2005; 7:443
- 425 Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., **Wilson PW**. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. *Diabetes* 2005; 54:3252-3257
- 426 **Wilson PW**, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. *Circulation* 2005; 112:3066-3072
- 427 **Wilson PW**, Nam BH, Pencina M, D'Agostino RB, Sr., Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. *Arch Intern Med* 2005; 165:2473-2478
- 428 Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, **Wilson PW**, D'Agostino RB, Vasan RS, Robins SJ. Increased Small Low-Density Lipoprotein Particle Number. A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study. *Circulation* 2006; 113: 20-29
- 429 Murabito JM, Pencina MJ, Nam BH, D'Agostino RB, Sr., Wang TJ, Lloyd-Jones D, **Wilson PW**, O'Donnell CJ. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. *JAMA* 2005; 294:3117-3123
- 430 **Wilson PWF**: Cardiovascular disease risk factors in women in Women and Heart Disease (eds Wenger NK, Collins P), Taylor and Francis 2005 (Abingdon, UK) p 17-31
- 431 Karasik D, Kiel DP, Kiely DK, Cupples LA, **Wilson PW**, O'donnell CJ, Felson DT. Abdominal Aortic Calcification and Exostoses at the Hand and Lumbar Spine: The Framingham Study. *Calcif Tissue Int* 2006; 78:1-8
- 432 Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liao CS, Richard AJ, Rother J, **Wilson PW**. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA* 2006; 295:180-189

- 433 Najarian RM, Sullivan LM, Kannel WB, **Wilson PW**, D'Agostino RB, Wolf PA. Metabolic Syndrome Compared With Type 2 Diabetes Mellitus as a Risk Factor for Stroke: The Framingham Offspring Study. *Arch Intern Med* 2006; 166:106-111
- 434 Meigs JB, O'Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, **Wilson PW**. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. *Diabetes* 2006; 55:530-537
- 435 Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, **Wilson PW**, D'Agostino RB, Vasan RS, Robins SJ. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. *Circulation* 2006; 113:20-29
- 436 **Wilson PWF**: Coronary heart disease risk: Origins, factors and utility. In Atlas of Cardiovascular Risk Factors (ed Gaziano JM) *Current Medicine* 2006, pp 37-48
- 437 Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, **Wilson PW**, Wolf PA, Levy D. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. *Circulation* 2006; 113(6):791-798
- 438 Thompson G, Morrell J, **Wilson P**: Dyslipidaemia in Clinical Practice (Second Edition) (Informa Healthcare 2006
- 439 **Wilson PW**, Ben Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD. Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study. *Atherosclerosis* 2006; 189: 364-368
- 440 Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liao CS, Mas JL, Richard AJ, Rother J, **Wilson PW**. The REDuction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. *Am Heart J* 2006; 151:e1-10.
- 441 Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF, Jr., **Wilson PW**, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. *Circulation* 2006; 113:1415-1423
- 442 Patel MR, Donahue M, **Wilson PW**, Califf RM. Clinical trial issues in weight-loss therapy. *Am Heart J* 2006; 151:633-642
- 443 Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT, **Wilson PW**, Kiel DP. Estradiol, Testosterone, and the Risk for Hip Fractures in Elderly Men from the Framingham Study. *Am J Med* 2006; 119:426-433
- 444 **Wilson PW**. Adiposity in youth and blood pressure. *Hypertension* 2006; 48:21-22
- 445 Patel MR, Donahue M, **Wilson PW**, Califf RM. Clinical trial issues in weight-loss therapy. *Am Heart J* 2006; 151:633-642
- 446 Meigs JB, Dupuis J, Liu C, O'Donnell CJ, Fox CS, Kathiresan S, Gabriel SB, Larson MG, Yang Q, Herbert AG, **Wilson PW**, Feng D, Tofler GH, Cupples LA. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample. *Obesity (Silver Spring)* 2006; 14:753-758
- 447 Meigs JB, **Wilson PW**, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006; 91:2906-2912
- 448 Lievers KJ, Kluijtmans LA, Blom HJ, **Wilson PW**, Selhub J, Ordovas JM. Association of a 31 bp VNTR in the CBS gene with postload homocysteine concentrations in the Framingham Offspring Study. *Eur J Hum Genet* 2006; 14(10):1125-1129
- 449 Kok HS, van Asselt KM, van der Schouw YT, van dT, I, Peeters PH, **Wilson PW**, Pearson PL, Grobbee DE. Heart disease risk determines menopausal age rather than the reverse. *J Am Coll Cardiol* 2006; 47:1976-1983
- 450 Brosius FC, III, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, **Wilson PW**. Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease. A Science Advisory From the American Heart Association Kidney and Cardiovascular Disease

- Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group Developed in Collaboration With the National Kidney Foundation. *Circulation* 2006; 114:1083-1087
- 451 Smith SR, **Wilson PW**. Free fatty acids and atherosclerosis--guilty or innocent? *J Clin Endocrinol Metab* 2006; 91: 2506-2508
- 452 O'Donnell CJ, Shea MK, Price PA, Gagnon DR, **Wilson PW**, Larson MG, Kiel DP, Hoffmann U, Ferencik M, Clouse ME, Williamson LM, Cupples LA, Dawson-Hughes B, Booth SL. Matrix Gla Protein Is Associated With Risk Factors for Atherosclerosis but not With Coronary Artery Calcification. *Arterioscler Thromb Vasc Biol* 2006; 26(12): 2769-2774
- 453 Rumawas ME, McKeown NM, Rogers G, Meigs JB, **Wilson PW**, Jacques PF. Magnesium intake is related to improved insulin homeostasis in the Framingham Offspring cohort. *J Am Coll Nutr* 2006; 25:486-492
- 454 Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, **Wilson PW**, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. *Arch Neurol* 2006; 63(11):1545-1550.
- 455 Lee DS, Evans JC, Robins SJ, **Wilson PW**, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol* 2007; 27:127-133
- 456 Scranton RE, Bozeman SR, Burton TM, Hoaglin DC, Sirko S, Hollenbeak CS, **Wilson PW**. Simple Demographic Model to Predict Multiple Cardiometabolic Risk Factors in Two Well-Known Observational Cohorts. *Value Health* 2007; 10:S37-S44
- 457 Steg PG, Bhatt DL, **Wilson PW**, D'Agostino R, Sr., Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. *JAMA* 2007; 297:1197-1206
- 458 Mainous AG III, Koopman RG, Diaz VA, Everett CJ, **Wilson PW**, Tilley BC. A coronary heart disease risk score based on patient-reported information. *Am.J.Cardiol.* 2007; 99:1236-1241
- 459 **Wilson PW**, Meigs, JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB, Sr. Prediction of Incident Diabetes Mellitus in Middle-aged Adults: The Framingham Offspring Study. *Arch.Intern.Med.* 2007; 167:1068-1074
- 460 Bellasi A, Lacey C, Taylor AJ, Raggi P, **Wilson PW**, Budoff MJ, Vaccarino V, Shaw LJ. Comparison of prognostic usefulness of coronary artery calcium in men versus women (results from a meta- and pooled analysis estimating all-cause mortality and coronary heart disease death or myocardial infarction). *Am J Cardiol* 2007; 100:409-414
- 461 Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, **Wilson PW**, Lackland DT, Lyons T, Jenkins AJ, Virella G. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. *Atherosclerosis* 2007; 190(2):359-369
- 462 Abell JE, Egan BM, **Wilson PW**, Lipsitz S, Woolson RF, Lackland DT. Age and race impact the association between BMI and CVD mortality in women. *Public Health Rep* 2007; 122:507-512
- 463 Dhingra R, Gona P, Nam BH, D'Agostino RB, Sr., **Wilson PW**, Benjamin EJ, O'Donnell CJ. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. *Am J Med* 2007; 120(12):1054-1062
- 464 Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, **Wilson PW**, Vaccarino V, Raggi P. Phosphorus levels are associated with subclinical atherosclerosis in the general population. *Atherosclerosis* 2007; 199: 424-431
- 465 Judd SE, Nanes MS, Ziegler TR, **Wilson PW**, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2008; 87(1):136-141

- 466 Abell JE, Egan BM, **Wilson PW**, Lipsitz S, Woolson RF, Lackland DT. Differences in cardiovascular disease mortality associated with body mass between Black and White persons. *Am J Public Health* 2008; 98(1):63-66
- 467 Dai J, Miller AH, Bremner JD, Goldberg J, Jones L, Shallenberger L, Buckham R, Murrah NV, Veledar E, **Wilson PW**, Vaccarino V. Adherence to the Mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. *Circulation* 2008; 117(2):169-175
PMCID:PMC3232063
- 468 Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D'Agostino R, Hirsch AT, **Wilson PW**, Steg PG. Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. *Cerebrovasc Dis* 2008; 25(4):366-374
- 469 Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, **Wilson PW**. Connective Tissue Growth factor and Susceptibility to Renal and Vascular Disease Risk in Type 1 Diabetes. *J Clin Endocrinol Metab* 2008; 93(5):1893-1900.
- 470 Freiberg MS, Pencina MJ, D'Agostino RB, Lanier K, **Wilson PW**, Vasani RS. BMI vs. waist circumference for identifying vascular risk. *Obesity (Silver Spring)* 2008; 16(2):463-469.
- 471 Levitzky YS, Cupples LA, Murabito JM, Kannel WB, Kiel DP, **Wilson PW**, Wolf PA, O'Donnell CJ. Prediction of intermittent claudication, ischemic stroke, and other cardiovascular disease by detection of abdominal aortic calcific deposits by plain lumbar radiographs. *Am J Cardiol* 2008; 101(3):326-331
- 472 Pearce EN, **Wilson PW**, Yang Q, Vasani RS, Braverman LE. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. *J Clin Endocrinol Metab* 2008; 93(3):888-894
- 473 Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB, Sr., **Wilson PW**, Meigs JB. Associations of Adiponectin, Resistin, and TNF-alpha with Insulin Resistance. *J Clin Endocrinol Metab* 2008; 93: 3165-72
- 474 Fox CS, Pencina MJ, **Wilson PW**, Paynter NP, Vasani RS, D'Agostino RB, Sr. Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study. *Diabetes Care* 2008; 31: 1582-1584
- 475 **Wilson PW**. CETP genes, metabolic effects, and coronary disease risk. (editorial) *JAMA* 2008; 299(23):2795-2796.
- 476 Mozaffarian D, **Wilson PW**, Kannel WB. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. *Circulation* 2008; 117(23):3031-3038
- 477 Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JE, Dube MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, **Wilson PW**, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the Science Conference. Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS Executive Summary. *Circulation* 2008; 118: 198-210
- 478 **Wilson PW**, Bozeman SR, Burton TM, Hoaglin DC, Ben Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. *Circulation* 2008; 118(2):124-130
- 479 Schambelan M, **Wilson PW**, Yarasheski KE, Cade WT, Davila-Roman VG, D'Agostino RB, Sr., Helmy TA, Law M, Mondy KE, Nachman S, Peterson LR, Worm SW. Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. *Circulation* 2008; 118(2):198-210
- 480 **Wilson PW**, Umpierrez GE. Insulin resistance and pubertal changes. (editorial) *J Clin Endocrinol Metab* 2008; 93(7):2472-2473
- 481 **Wilson PW**. Cardiovascular risk assessment-where are we going? (editorial) *Prev Cardiol* 2008; 11(3):183-184
- 482 **Wilson PW**, Narayan KV. Low-cost strategies to predict cardiovascular disease. (editorial) *Nat Clin Pract Cardiovasc Med* 2008; 5: 518-519

- 483 Abell JE, Egan BM, **Wilson PW**, Lipsitz S, Woolson RF, Lackland DT. Differences in cardiovascular disease mortality associated with body mass between Black and White persons. *Am J Public Health* 2008; 98(1):63-66.
- 484 Dai J, Jones DP, Goldberg J, Ziegler TR, Bostick RM, **Wilson PW**, Manatunga AK, Shallenberger L, Jones L, Vaccarino V. Association between adherence to the Mediterranean diet and oxidative stress. *Am J Clin Nutr* 2008; 88(5):1364-1370.
- 485 Frankel DS, Meigs JB, Massaro JM, **Wilson PW**, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. *Circulation* 2008; 118(24):2533-2539.
- 486 Freiberg MS, Pencina MJ, D'Agostino RB, Lanier K, **Wilson PW**, Vasan RS. BMI vs. waist circumference for identifying vascular risk. *Obesity (Silver Spring)* 2008; 16(2):463-469.
- 487 Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liao CS, Hirsch AT, Mas JL, **Wilson PW**, Corbalan R, Aichner F, Steg PG. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. *Am Heart J* 2008; 156(5):855-863.
- 488 Goyal A, Nerenberg K, Gerstein HC, Umpierrez G, **Wilson PW**. Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. *Diab Vasc Dis Res* 2008; 5(4):276-284.
- 489 Judd SE, Nanes MS, Ziegler TR, **Wilson PW**, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2008; 87(1):136-141.
- 490 Levitzky YS, Cupples LA, Murabito JM, Kannel WB, Kiel DP, **Wilson PW**, Wolf PA, O'Donnell CJ. Prediction of intermittent claudication, ischemic stroke, and other cardiovascular disease by detection of abdominal aortic calcific deposits by plain lumbar radiographs. *Am J Cardiol* 2008; 101(3):326-331.
- 491 Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D, Fox CS, Wang TJ, **Wilson PW**, Kannel WB, Vasan RS. Plasma leptin levels and incidence of heart failure, cardiovascular disease and total mortality in the elderly. *Diabetes Care* 2009 32(4): 612-6 PMID:PMC2660448
- 492 Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liao CS, Rother J, **Wilson PW**, Richard AJ, Eagle KA, Ohman EM. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. *Eur Heart J* 2008; 29(24):3052-3060.
- 493 Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, **Wilson PW**, D'Agostino RB, Sr., Cupples LA. Genotype score in addition to common risk factors for prediction of type 2 diabetes. *N Engl J Med* 2008; 359(21):2208-2219
- 494 Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, **Wilson PW**, Kritchevsky SB: Incident heart failure prediction in the elderly: the health ABC heart failure score. *Circ.Heart Fail.* 2008 Jul;1(2):125-33. PMID:PMC2748334
- 495 Rutter MK, **Wilson PW**, Sullivan LM, Fox CS, D'Agostino RB, Sr., Meigs JB. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. *Circulation* 2008; 117(8):1003-1009.
- 496 Goyal A, Nerenberg K, Gerstein HC, Umpierrez G, **Wilson PW**. Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. *Diab.Vasc.Dis.Res.* 2008 Nov;5(4):276-84
- 497 **Wilson PW**. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. *Am J Med* 2008; 121(10 Suppl 1):S15-S20.
- 498 **Wilson PW**, Bozeman SR, Burton TM, Hoaglin DC, Ben Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. *Circulation* 2008; 118(2):124-130.

- 499 **Wilson PWF**, Pencina M, Jacques P, Selhub J, D'Agostino R, O'Donnell CJ: C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. *Circ Cardiovasc Qual Outcomes* 2008; 1: 92-97
- 500 **Wilson PWF**: Progressing from Risk Factors to Omics: *Circ Cardiovas Genet*: 2008; 1: 141-146
- 501 Chen TH, Gona P, Sutherland PA, Benjamin EJ, **Wilson PW**, Larson MG, Vasan RS, Robins SJ. Long-term C-reactive protein variability and prediction of metabolic risk. *Am J Med* 2009; 122(1):53-61.
- 502 **Wilson PW**, Narayan VKM. New York City Health and Nutrition Examination Survey: a model for urban health surveillance. *Diabetes Care* 2009; 32(1):204-205.
- 503 Brown WV, Fujioka K, **Wilson PW**, Woodworth KA. Obesity: why be concerned? *Am.J.Med* 2009 Apr;122(4 Suppl 1):S4-11
- 504 Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE, Jr., Howard BV, Howard VJ, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. *Circulation* 2009 May 5;119(17):2408-16
- 505 Jackson D, White I, Kostis JB, Wilson AC, Folsom AR, Wu K, Chambless L, Benderly M, Goldbourt U, Willeit J, et al. Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. *Stat.Med.* 2009 Apr 15;28(8):1218-37
- 506 Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, Rodondi N, Satterfield S, Bauer DC, Bibbins-Domingo K, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. *Arch.Intern.Med.* 2009 Apr 13;169(7):708-15
- 507 Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D, Fox CS, Wang TJ, **Wilson PW**, Kannel WB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. *Diabetes Care* 2009 Apr;32(4):612-6. PMID:PMC2660448
- 508 Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. *Clin.Chem.* 2009 Feb;55(2):378-84
- 509 Raz I, **Wilson PW**, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. *Diabetes Care* 2009 Mar;32(3):381-6. PMID:PMC2646013
- 510 Sposito AC, Ramires JA, Jukema JW, Molina JC, Silva PM, Ghadanfar MM, **Wilson PW**. Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. *Curr.Med.Res.Opin.* 2009; 25: 1171-1178
- 511 Tucker AM, Vogel RA, Lincoln AE, Dunn RE, Ahrensfield DC, Allen TW, Castle LW, Heyer RA, Pellman EJ, Strollo PJ, Jr., et al. Prevalence of cardiovascular disease risk factors among National Football League players. *JAMA* 2009 May 27;301(20):2111-9
- 512 **Wilson PW**. Risk scores for prediction of coronary heart disease: an update. *Endocrinol.Metab Clin.North Am* 2009 Mar;38(1):33-44
- 513 Kalogeropoulos A, Georgiopoulou V, Harris TB, Kritchevsky SB, Bauer DC, Smith AL, Strotmeyer E, Newman AB, **Wilson PW**, Psaty BM, et al. Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study. *J.Card Fail.* 2009 Sep;15(7):593-9
- 514 Schnabel R, Dupuis J, Larson MG, Lunetta KL, Robins SJ, Zhu Y, Rong J, Yin X, Stirnadel HA, Nelson JJ, et al. Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. *Atherosclerosis* 2009 Jun;204(2):601-7
- 515 Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, **Wilson PW**, Mas JL, Rother J. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. *Stroke* 2009 Feb;40(2):350-4

- 516 Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, Salette G, Goto S, Smith SC, Jr., Liau CS, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. *Eur.Heart J.* 2009; 30: 2318-2326
- 517 Butler J, Kalogeropoulos A, Georgiopoulou V, de RN, Rodondi N, Smith AL, Hoffmann U, Kanaya A, Newman AB, Kritchevsky SB, Vasani RS, **Wilson PW**, Harris TB. Serum Resistin Concentrations and Risk of New Onset Heart Failure in Older Persons. The Health, Aging, and Body Composition (Health ABC) Study. *Arterioscler Thromb Vasc Biol* 2009; 29: 1144-1149
- 518 Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC, Jr., **Wilson PW**, Watson KE, Steg PG. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. *Am Heart J* 2009; 158(6):1038-1045.
- 519 Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, **Wilson PW**. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. *Clin Chem* 2009; 55(2):378-384.
- 520 **Wilson PW**. Challenges to improve coronary heart disease risk assessment. *JAMA* 2009; 302(21):2369-2370.
- 521 **Wilson PW**. Risk scores for prediction of coronary heart disease: an update. *Endocrinol Metab Clin North Am* 2009; 38(1):33-44
- 522 Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Rother J, Goto S, Pasquet B, **Wilson PW**. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). *Am.J.Cardiol.* 2010 Mar 1;105(5):667-71
- 523 Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, **Wilson PW**, Ohman EM, Brennan DM, D'Agostino RB, Bhatt DL, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. *Eur.Heart J.* 2010; 31: 1257-1265
- 524 Twombly JG, Long Q, Zhu M, **Wilson PW**, Venkat NK, Fraser LA, Webber BC, Phillips LS. Diabetes care in black and white Veterans In The Southeastern United States *Diabetes Care* 2010; 33(5):958-63. PMID:PMC2858198
- 525 Fraser LA, Twombly J, Zhu M, Long Q, Hanfelt JJ, Narayan KM, **Wilson PW**, Phillips LS. Delay in diagnosis of diabetes is not the patient's fault. *Diabetes Care* 2010 Jan;33(1):e10
- 526 Hivert MF, Sullivan LM, Shrader P, Fox CS, Nathan DM, D'Agostino RB, Sr., **Wilson PW**, Benjamin EJ, Meigs JB. The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. *Metabolism* 2010 Apr;59(4):540-6. PMID:PMC2843788
- 527 Dai J, Ziegler TR, Bostick RM, Manatunga AK, Jones DP, Goldberg J, Miller A, Vogt G, **Wilson PW**, Jones L, et al. High habitual dietary {alpha}-linolenic acid intake is associated with decreased plasma soluble interleukin-6 receptor concentrations in male twins. *Am.J.Clin.Nutr.* 2010 May 12;
- 528 Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, **Wilson PW**, Schaefer EJ. Small Dense LDL Cholesterol and Coronary Heart Disease: Results from the Framingham Offspring Study. *Clin.Chem.* 2010; 56: 967-976
- 529 Kalogeropoulos A, Psaty BM, Vasani RS, Georgiopoulou V, Smith AL, Smith NL, Kritchevsky SB, **Wilson PW**, Newman AB, Harris TB, et al. Validation of the Health ABC Heart Failure Model for Incident Heart Failure Risk Prediction: The Cardiovascular Health Study. *Circ.Heart Fail.* 2010; 169; 708-715
- 530 Dai J, Lampert R, **Wilson PW**, Goldberg J, Ziegler TR, Vaccarino V. Mediterranean Dietary Pattern Is Associated With Improved Cardiac Autonomic Function Among Middle-Aged Men: A Twin Study. *Circ.Cardiovasc.Qual.Outcomes.* 2010; 3: 366-373

- 531 Rice TB, Dunn RE, Lincoln AE, Tucker AM, Vogel RA, Heyer RA, Yates AP, **Wilson PW**, Pellmen EJ, Allen TW, et al. Sleep-disordered breathing in the National Football League. *Sleep* 2010 Jun 1;33(6):819-24. PMID:PMC2881715
- 532 Palaniappan LP, Araneta MR, Assimes TL, Barrett-Connor EL, Carnethon MR, Criqui MH, Fung GL, Narayan KM, Patel H, Taylor-Piliae RE, et al. Call to Action: Cardiovascular Disease in Asian Americans. A Science Advisory From the American Heart Association. *Circulation* 2010; 122: 1242-1252
- 533 Goyal A, Norton CR, Thomas TN, Davis RL, Butler J, Ashok V, Zhao L, Vaccarino V, **Wilson PW**. Predictors of Incident Heart Failure in a Large Insured Population: A One Million Person-Year Follow-up Study. *Circ.Heart Fail.* 2010; 3: 698-705
- 534 Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, **Wilson PW**, Alberts MJ, D'Agostino R, Liao CS, et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. *JAMA* 2010; 304: 1350-1357
- 535 **Wilson PW**. Preface-Global impact of the Framingham Heart Study. *Prog.Cardiovasc.Dis.* 2010 Jul;53(1):3
- 536 **Wilson PW**. Improving the landscape for prevention. *Prev.Cardiol.* 2010;13(3):145
- 537 Le NA, **Wilson PW**. How Do We Find the Best Biomarkers for Cardiovascular Disease? *Clin Chem* 2010; 56: 1658-1659
- 538 Otokoza S, Ai M, Asztalos BF, White CC, Demissie-Banjaw S, Cupples LA, Nakajima K, **Wilson PW**, Schaefer EJ. Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: Results from the Framingham Offspring Study. *Atherosclerosis* 2010; 213: 251-255
- 539 Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, **Wilson PW**, Kirkman MS. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation. *Circulation* 2010; 121: 2694-2701
- 540 Roussel R, Travert F, Pasquet B, **Wilson PW**, Smith SC, Jr., Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG. Metformin use and mortality among patients with diabetes and atherothrombosis. *Arch Intern Med* 2010; 170(21):1892-1899
- 541 Shaw LJ, **Wilson PW**, Hachamovitch R, Hendel RC, Borges-Neto S, Berman DS. Improved Near-Term Coronary Artery Disease Risk Classification With Gated Stress Myocardial Perfusion SPECT. *JACC Cardiovasc Imaging* 2010; 3(11):1139-1148.
- 542 Twombly JG, Long Q, Zhu M, Fraser LA, Olson DE, **Wilson PW**, Narayan KM, Phillips LS. Validity of the primary care diagnosis of diabetes in veterans in the southeastern United States. *Diabetes Res Clin Pract* 2010.
- 543 Heidenreich PA, Trogon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, **Wilson PW**, Woo YJ. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association. *Circulation* 2011; 123: 933-944
- 544 Hivert MF, Sullivan LM, Shrader P, Fox CS, Nathan DM, D'Agostino RB, Sr., **Wilson PW**, Kowall B, Herder C, Meisinger C, Thorand B, Rathmann W, Meigs JB. Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. *Diabetologia* 2011; 54: 1019-1024
- 545 Shara NM, Wang H, Valaitis E, Pehlivanova M, Carter EA, Resnick HE, Wang W, Umans JG, Lee ET, Howard BV, Devereux RB, **Wilson PW**. Comparison of estimated glomerular filtration rates and albuminuria in predicting risk of coronary heart disease in a population with high prevalence of diabetes mellitus and renal disease. *Am J Cardiol* 2011; 107(3):399-405.

- 546 **Wilson PW**. Prediction of cardiovascular disease events. *Cardiol Clin* 2011; 29(1):1-13.
- 547 **Wilson PW**, D'Agostino RB, Fox CS, Sullivan LM, Meigs JB. Type 2 diabetes risk in persons with dysglycemia: The Framingham Offspring Study. *Diabetes Res Clin Pract* 2011; 92: 124-127
- 548 Ai M, Otokoza S, Asztalos BF, White CC, Cupples LA, Nakajima K, Lamon-Fava S, **Wilson PW**, Matsuzawa Y, Schaefer EJ. Adiponectin: An independent risk factor for coronary heart disease in men in the Framingham offspring Study. *Atherosclerosis* 2011 Aug;217(2):543-8
- 549 Bidulescu A, Liu J, Musani SK, Fox ER, Samdarshi TE, Sarpong DF, Vaccarino V, **Wilson PW**, Arnett DK, Din-Dzietham R, et al. Association of Adiponectin with Left Ventricular Mass in African Americans: The Jackson Heart Study. *Circ.Heart Fail.* 2011; 4: 747-753
- 550 **Wilson PW**. Remembering William B. Kannel, MD, MPH (1923-2011). *J.Clin.Lipidol.* 2011 Nov;5(6):501-2
- 551 Bukowski R, Davis KE, **Wilson PW**. Delivery of a small for gestational age infant and greater maternal risk of ischemic heart disease. *PLoS.ONE.* 2012;7(3):e33047. PMID:PMC3303879
- 552 Dallongeville J, Bhatt DL, Steg PH, Ravnaud P, **Wilson PW**, Eagle KA, Goto S, Mas JL, Montalescot G. Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. *Eur.J.Prev.Cardiol.* 2012 Apr;19(2):241-9
- 553 Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, Simonsick E, Satterfield S, Newman AB, **Wilson PW**, Pletcher MJ, et al. Framingham risk score and alternatives for prediction of coronary heart disease in older adults. *PLoS.ONE.* 2012;7(3):e34287. PMID:PMC3314613
- 554 Roussel R, Hadjadj S, Pasquet B, **Wilson PW**, Smith SC, Jr., Goto S, Tubach F, Marre M, Porath A, Krempf M, et al. Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice: Brief title: Thiazolidinedione use and mortality. *Int.J.Cardiol.* 2012 May 4;
- 555 Vesper HW, **Wilson PW**, Rifai N. A message from the laboratory community to the National Cholesterol Education Program Adult Treatment Panel IV. *Clin.Chem.* 2012 Mar;58(3):523-7
- 556 **Wilson PW**, D'Agostino R, Sr., Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, et al. An international model to predict recurrent cardiovascular disease. *Am.J.Med* 2012 Jul;125(7):695-703
- 557 Gaziano JM, **Wilson PW**. Cardiovascular risk assessment in the 21st century. *JAMA* 2012 Aug 22;308(8):816-7
- 558 **Wilson PW**. Insulin resistance and ischemic myocardial injury post-percutaneous coronary interventions. *JACC.Cardiovasc.Interv.* 2012 Nov;5(11):1168-9
- 559 Eapen DJ, Manocha P, Patel RS, Hammadah M, Veledar E, Wassel C, Nanjundappa RA, Sikora S, Malayter D, **Wilson PW**, et al. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. *J Am.Coll.Cardiol.* 2013 Jul 23;62(4):329-37
- 560 Bukowski R, Davis KE, **Wilson PW**. Delivery of a small for gestational age infant and greater maternal risk of ischemic heart disease. *PLoS.ONE.* 2012;7(3):e33047. PMID:PMC3303879
- 561 Dallongeville J, Bhatt DL, Steg PH, Ravnaud P, **Wilson PW**, Eagle KA, Goto S, Mas JL, Montalescot G. Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. *Eur.J.Prev.Cardiol.* 2012 Apr;19(2):241-9
- 562 Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, **Wilson PW**. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. *J.Am.Heart Assoc.* 2013 Aug;2(4):e000037. PMID:PMC3828803
- 563 Ridker PM, **Wilson PW**. A trial-based approach to statin guidelines. *JAMA* 2013 Sep 18;310(11):1123-4
- 564 Udell JA, Steg PG, Scirica BM, Eagle KA, Ohman EM, Goto S, Alsheikh-Ali AA, Porath A, Corbalan R, Umez-Eronini AA, **Wilson PW** et al. Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. *Eur.J Prev.Cardiol.* 2013 Aug 5

- 565 Le NA, Farkas-Epperson M, Sweeney ME, **Wilson PW**, Virgil BW. Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. *Atherosclerosis* 2013 Dec;231(2):268-73
- 566 Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson J, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, **Wilson PW**: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013 Nov 12; also in *J.Am.Coll.Cardiol.* 2013 Nov 12
- 567 Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, **Wilson PW**: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013 Nov 12; also in *J.Am.Coll.Cardiol.* 2013 Nov 7;
- 568 Le NA, Farkas-Epperson M, Sweeney ME, **Wilson PW**, Brown VB. Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. *Atherosclerosis* 2013 Dec;231(2):268-736.
- 569 Wilson PW. Lipids and vascular disease: a Framingham perspective. *Global heart.* 2013;8(1):25-33. doi: 10.1016/j.gheart.2012.12.009. PubMed PMID: 25690261.
- 570 Khan H, Kalogeropoulos AP, Zannad F, Marti CN, **Wilson PW**, Georgiopoulou VV, Kanaya AM, Newman AB, Schelbert E, Harris TB, et al. Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study. *Eur.J.Heart Fail.* 2014 Feb 27;
- 571 Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, **Wilson PW**, Fried L. KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. *Am.J.Kidney Dis.* 2014 Nov 18;
- 572 Rutter MK, Sullivan LM, Fox CS, **Wilson PW**, Nathan DM, Vasani RS, D'Agostino RB, Sr., Meigs JB. Baseline levels, and changes over time in body mass index and fasting insulin, and their relationship to change in metabolic trait clustering. *Metab Syndr.Relat Disord.* 2014 Sep;12(7):372-80. PMID:PMC4209491
- 573 Potier L, Roussel R, Labreuche J, Marre M, Cacoub P, Rother J, **Wilson PW**, Goto S, Bhatt DL, Steg PG. Interaction between diabetes and a high ankle-brachial index on mortality risk. *Eur.J.Prev.Cardiol.* 2014 Apr 29;
- 574 Khan H, Kalogeropoulos AP, Zannad F, Marti CN, **Wilson PW**, Georgiopoulou VV, Kanaya AM, Newman AB, Schelbert E, Harris TB, et al. Incident heart failure in relation to vascular disease: insights from the Health, Aging, and Body Composition Study. *Eur.J.Heart Fail.* 2014 May;16(5):526-33
- 575 Ridker PM, **Wilson PW**. Formulation of treatment recommendations for statins--reply. *Jama.* 2014;311(3):306. doi: 10.1001/jama.2013.284481. PubMed PMID: 24430330.
- 576 Udell JA, Steg PG, Scirica BM, Eagle KA, Ohman EM, Goto S, Alsheikh-Ali AA, Porath A, Corbalan R, Umez-Eronini AA, Hoffman EB, **Wilson PW**, Bhatt DL, Reduction of Atherothrombosis for Continued Health Registry I. Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. *European journal of preventive cardiology.* 2014;21(12):1531-40. PubMed PMID: 23918840.
- 577 Bonifante A, Ayer T, Veledar E, Clark A, **Wilson PW**. Antecedent blood pressure as a predictor of cardiovascular disease. *Journal of the American Society of Hypertension : JASH.* 2015;9(9):690-6 e1. PubMed PMID: 26260423.
- 578 Cavender MA, Steg PG, Smith SC, Jr., Eagle K, Ohman EM, Goto S, Kuder J, Im K, **Wilson PW**, Bhatt DL, Investigators RR. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. *Circulation.* 2015;132(10):923-31. PubMed PMID: 26152709.

- 579 Le NA, Tomassini JE, Tershakovec AM, Neff DR, **Wilson PW**. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. *Journal of the American Heart Association*. 2015;4(10):e001675. PubMed PMID: 26486166.
- 580 Martin SS, Sperling LS, Blaha MJ, **Wilson PW**, Gluckman TJ, Blumenthal RS, Stone NJ. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. *Journal of the American College of Cardiology*. 2015;65(13):1361-8. doi: PubMed PMID: 25835448; PubMed Central PMCID: PMC4760944.
- 581 Olson DE, Zhu M, Long Q, Barb D, Haw JS, Rhee MK, Mohan AV, Watson-Williams PI, Jackson SL, Tomolo AM, **Wilson PW**, Narayan KM, Lipscomb J, Phillips LS. Increased cardiovascular disease, resource use, and costs before the clinical diagnosis of diabetes in veterans in the southeastern U.S. *Journal of general internal medicine*. 2015;30(6):749-57. PubMed PMID: 25608739; PubMed Central PMCID: PMC4441670.
- 582 Tucker AM, Lincoln AE, Vogel RA, Black HR, Dunn RE, **Wilson PW**, Pellman EJ. Lack of blood pressure difference by race in professional American football players. *Journal of the American Society of Hypertension : JASH*. 2015;9(5):370-4. PubMed PMID: 25979411.
- 583 Tofler GH, Massaro J, O'Donnell CJ, **Wilson PW**, Vasani RS, Sutherland PA, Meigs JB, Levy D, D'Agostino RB, Sr. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. *Thrombosis research*. 2016;140:30-5. PubMed PMID: 26896607.
- 584 **Wilson PW**. Changing Cholesterol Levels and Coronary Heart Disease Risk. *Circulation*. 2016;133(3):239-41. PubMed PMID: 26659947.
- 585 **Wilson PW**, Bloom HL. Caffeine Consumption and Cardiovascular Risks: Little Cause for Concern. *Journal of the American Heart Association*. 2016;5(1). PubMed PMID: 26813891.
- 586 Coakley KE, Felner EI, Tangpricha V, **Wilson PW**, Singh RH. Impact of Dietary Intake on Bone Turnover in Patients with Phenylalanine Hydroxylase Deficiency. *JIMD reports*. 2017. Epub 2017/01/29. doi: 10.1007/8904_2016_39. PubMed PMID: 28130717.
- 587 Kim JH, Ko YA, Hedley J, MacNamara J, Awad M, Taylor W, Healy S, Aida H, Le NA, **Wilson PW**, White M, Sperling LS, Wilson JS, Jr., Baggish AL. The impact of moderate distance recreational running and ageing on cardiac physiology. *Heart*. 2017;103(3):219-26. Epub 2016/08/18. doi: 10.1136/heartjnl-2016-310059. PubMed PMID: 27530134.
- 588 **Wilson PW**, D'Agostino RB, Sr. No One Size Fits All: Scoring Risk of In-Hospital Death After Myocardial Infarction. *J Am Coll Cardiol*. 2016;68:636-8.
- 589 **Wilson PW**, Pencina MJ. Estimation of Risk for Initial Atherosclerotic Cardiovascular Disease Events: Taking Stock and Moving Forward. *Circulation*. 2016;134:1792-1793.
- 590 Coakley KE, Felner EI, Tangpricha V, **Wilson PWF** and Singh RH. Impact of Dietary Intake on Bone Turnover in Patients with Phenylalanine Hydroxylase Deficiency. *JIMD reports*. 2017;36:67-77.
- 591 Jackson SL, Safo SE, Staimez LR, Olson DE, Narayan KMV, Long Q, Lipscomb J, Rhee MK, **Wilson PWF**, Tomolo AM and Phillips LS. Glucose challenge test screening for prediabetes and early diabetes. *Diabet Med*. 2017;34:716-724.
- 592 Kim JH, Ko YA, Hedley J, MacNamara J, Awad M, Taylor W, Healy S, Aida H, Le NA, **Wilson PW**, White M, Sperling LS, Wilson JS, Jr. and Baggish AL. The impact of moderate distance recreational running and ageing on cardiac physiology. *Heart*. 2017;103:219-226.
- 593 Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen YI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dube MP, Ebeling T, Eiriksdottir G, Esko T, Farmaki AE, Feitosa MF, Ferrario M,

- Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin MR, Jensen GB, Jorgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJF, Lu Y, Lu X, Magi R, Malarstig A, Manichaikul A, Manning AK, Mantyselka P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, Muller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O'Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renstrom F, Rich SS, Ridker PM, Rioux JD, Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, Stirrups KE, Stitzel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, Tardif JC, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam NR, Varbo A, Varga TV, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, Weeke PE, Weinstock J, Wessel J, Wilson JG, **Wilson PWF**, Xu M, Yaghoobkar H, Young R, Zeggini E, Zhang H, Zheng NS, Zhang W, Zhang Y, Zhou W, Zhou Y, Zoledziewska M, Charge Diabetes Working G, Consortium EP-I, Consortium E-C, Consortium G, Program VAMV, Howson JMM, Danesh J, McCarthy MI, Cowan CA, Abecasis G, Deloukas P, Musunuru K, Willer CJ and Kathiresan S. Exome-wide association study of plasma lipids in >300,000 individuals. *Nature genetics*. 2017;49:1758-1766.
- 594 Navar AM, Wang TY, Li S, Robinson JG, Goldberg AC, Virani S, Roger VL, **Wilson PWF**, Ellassal J, Lee LV and Peterson ED. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. *Am Heart J*. 2017;193:84-92.
- 595 Sandesara PB, Ramjee V, Ghasemzadeh N, Guo Y, Bhatia N, Li Q, Vaughn L, Nell-Dybdahl C, Waller EK, Mahar EA, Brigham K, **Wilson PWF**, Quyyumi A, Le NA and Sperling LS. Circulating progenitor cells in patients with familial hypercholesterolemia. *J Clin Apher*. 2017.
- 596 **Wilson PW**, Suther CS, Bain MM, Icken W, Jones A, Quinlan-Pluck F, Olori V, Gautron J and Dunn IC. Understanding avian egg cuticle formation in the oviduct: a study of its origin and deposition. *Biol Reprod*. 2017;97:39-49.
- 597 **Wilson PWF**. Development and Progression of Coronary Artery Calcification. *JACC Cardiovascular imaging*. 2017;10:867-868.
- 598 **Wilson PWF**, Gagnon D. Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors: A Challenge to Improve Usual Care. *Circulation*. 2017;136:1204-1206.
- 599 **Wilson PWF**, Shaw LJ. Risk assessment with newer statistical metrics. *Stat Med*. 2017;36:4509-4510.
- 600 Arya S, Binney Z, Khakharia A, Brewster LP, Goodney P, Patzer R, Hockenberry J and **Wilson PWF**. Race and Socioeconomic Status Independently Affect Risk of Major Amputation in Peripheral Artery Disease. *Journal of the American Heart Association*. 2018;7.
- 601 Arya S, Binney ZO, Khakharia A, Long CA, Brewster LP, **Wilson PW**, Jordan WD, Jr. and Duwayri Y. High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. *J Vasc Surg*. 2018;67:217-228 e1.
- 602 Arya S, Khakharia A, Binney ZO, DeMartino RR, Brewster LP, Goodney PP and **Wilson PWF**. Statins Have a Dose-Dependent Effect on Amputation and Survival in Peripheral Artery Disease Patients. *Circulation*. 2018.
- 603 Arya S, Khakharia A, Binney ZO, DeMartino RR, Brewster LP, Goodney PP and **Wilson PWF**. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease.

- Circulation*. 2018;137:1435-1446.
- 604 Djousse L, Ho YL, Nguyen XT, Gagnon DR, **Wilson PWF**, Cho K, Gaziano JM and Program VAMV. DASH Score and Subsequent Risk of Coronary Artery Disease: The Findings From Million Veteran Program. *Journal of the American Heart Association*. 2018;7.
- 605 Nanna MG, Navar AM, Zakrofsky P, Xiang Q, Goldberg AC, Robinson J, Roger VL, Virani SS, **Wilson PWF**, Ellassal J, Lee LV, Wang TY and Peterson ED. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. *JAMA Cardiol*. 2018.
- 606 Navar AM, Peterson ED, Li S, Robinson JG, Roger VL, Goldberg AC, Virani S, **Wilson PWF**, Nanna MG, Lee LV, Ellassal J and Wang TY. Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. *Circ Cardiovasc Qual Outcomes*. 2018;11:e004249.
- 607 Nguyen XT, Quaden RM, Wolfrum S, Song RJ, Yan JQ, Gagnon DR, **Wilson PWF**, Cho K, O'Donnell C, Gaziano JM, Djousse L and Program VAMV. Prevalence of Ideal Cardiovascular Health Metrics in the Million Veteran Program. *Am J Cardiol*. 2018;122:347-352.
- 608 Shaw LJ, Goyal A, Mehta C, Xie J, Phillips L, Kelkar A, Knapper J, Berman DS, Nasir K, Veledar E, Blaha MJ, Blumenthal R, Min JK, Fazel R, **Wilson PWF** and Budoff MJ. 10-Year Resource Utilization and Costs for Cardiovascular Care. *J Am Coll Cardiol*. 2018;71:1078-1089.
- 609 Vassy JL, Ho YL, Honerlaw J, Cho K, Gaziano JM, **Wilson PWF** and Gagnon DR. Yield and bias in defining a cohort study baseline from electronic health record data. *J Biomed Inform*. 2018;78:54-59.